1www.wholesaleinvestor.com.au

Emerging biotech with unique vaccine technology (15)

Wholesaler of premium infant milk to the growing Chinese market (26)

Technology provider to international hotels with a software solution for bandwidth efficiency (33)

ASX-listed payments provider focused on emerging markets (30)

Medical device and software company (14)

Investment Opportunities for Wholesale, Sophisticated & High Net Worth Investors

Oc

tob

er

20

11

Medical device company targeting the reconstructive surgery market (10)

Don’t miss your opportunity to attend the Australasian Life Science Investment Summit 2011.

To register for this event or for more information contact Hayley Laing

w. www.ausbiotech2011.com.au/alsise. hlaing@ausbiotech.orgp: +61 3 9828 1400

Australasian Life Science Investment Summit

2011 9.00am – 5.30pm

Wednesday 19 October 2011 Adelaide Convention Centre, South Australia

Proudly supported by

Media PartnersProudly supported by

Brought to you by

InvestmentAUSTRALIA’S BIOTECHNOLOGY ORGANISATION

• Attendance is free for bonafide investors. Limited to 200 places.

• Presentations from 40 high-growth public and private life science companies.

• Excellent networking opportunities available with catering provided throughout the day.

Who should attend: • HNW and private

investors

• Professional investors

• Brokers

• VC representatives

• Private Equity firms

• Fund Managers

• Analysts

The Investment Summit is part of Australia’s premier biotechnology industry conference, AusBiotech 2011, and will be held at the Adelaide Convention Centre on Wednesday 19 October from 9.00am until 5.30pm.

REGISTER NOW / www.ausbiotech2011.com.au/alsis

Contents

OCTOBER 2011Wholesale Investor Magazine is published by:

Wholesale Investor Pty Ltd

ACN 131 512 715

Managing Director - Steve Torso

Publisher - Reuben Buchanan

Editor - Lachlan Colquhoun/Claudia Holt

General Manager - Kimber Rothwell

Senior Account Managers:- Daniel Coombes- Jason Ballo

Directors

Reuben Buchanan – Executive DirectorDomenic Carosa – Non Executive Director

Advisory board Tim Trumper

Sydney:

Address - Suite 204, 66 King St. SydneyPhone - 1300 597 595Web - www.wholesaleinvestor.com.au

Editorial Enquiries

editorial@wholesaleinvestor.com.au

Advertising Enquiries

advertising@wholesaleinvestor.com.au

Listing Enquiries

capital@wholesaleinvestor.com.au

1300 597 595

Subscription Enquiries

subscribe@wholesaleinvestor.com.au

Design - Bubblefish Designwww.bubblefish.com.au

Printer - GEON Groupwww.geongroup.com

Distribution - GEON Groupwww.geongroup.com

Disclaimer

This Publication contains prominent statements

appropriate for the particular medium by which

the Publication is made to the effect that:

(A) the information contained in the Publication

about the proposed business opportunity

and the securities or scheme interests is not

intended to be the only information on which

the investment decision is made and is not a

substitute for a disclosure document, Product

Disclosure Statement or any oth er notice that

may be required under the Act, as that Act may

apply to the investment. Detailed information may

be needed to make an investment decision, for

example: financial statements; a business plan;

information about ownership of intellectual or

industrial property; or expert opinions including

valuations or auditors’ reports; and

(B) a prospective investor is strongly advised

to take appropriate professional advice before

accepting an offer for issue or sale of any

securities or scheme interests;

For more information, please visit our website

www.wholesaleinvestor.com.au or email

info@wholesaleinvestor.com.au

Editorial

4 Letter from the Managing Director

5 Upcoming Events

6 Company Updates

8 ZORK Seals Deal with US Investor

9 Investing in Early Growth Companies

Opportunities

10 Mesynthes Ltd

11 Benitec Ltd (ASX:BLT)

12 Eastland Medical Systems Ltd (ASX:EMS)

13 Jubilent Health Australia Ltd

14 Global Kinetics Corporation

15 BioDiem Ltd (ASX:BDM)

16 WH Medical

17 Phylogica Limited (ASX:PYC)

18 Photonz Corporation Ltd

19 Xenexus Pharmaceuticals Pty Ltd

20 Cynergy

21 Diamond Energy Pty Ltd

22 EcoQuest (ASX:ECQ)

24 KFSU Ltd

25 Sun Connect Pty Ltd

26 Eastern Harmony New Zealand Ltd

27 Bluechiip Ltd (ASX:BCT)

28 Equiome Pty Ltd

29 Collective Intelligence Group Pty Ltd

30 Mint Wireless Ltd (ASX:MNW)

31 Because Group International Ltd

32 Exa Web Solutions

33 Qanda Technology Ltd (ASX:QNA)

34 Intellect Projects Pty Ltd

35 BlackWall SPORTSMED Property Trust

36 TRAC Financial Ltd

37 Folkestone Ltd (ASX:FLK)

38 Bizpanel Limited

39 Bullion Capital

40 Flinders Resources Ltd

43 Listing Page

4

Letter from the Managing Director

These are challenging times in the public markets, but that is not stopping astute investors from seeking out high quality private companies. With all the turmoil, investors and corporates are making a return to cash, but the upside of that is that they are ready to invest when they see the right opportunities.

Wholesale Investor’s recent survey highlighted the key areas of interest. Mining and mining services, healthcare and life sciences, cleantech and greentech, the online digital space and agriculture were the Top 5 sectors for investor focus over the next six months.

For the first time, we also asked investors what stage in the business cycle they were interested in. At what point did they want to see the opportunities? The number one answer: early growth, followed by commercialization and start-up, then seed and for expansion.

In previous surveys we have seen a healthy level of interest in offshore markets. This time, we asked investors which international stock exchanges were on their radar for small cap opportunities.

We learned from you that Singapore was number one, followed by Hong Kong, London (both LSE and AIM), then Toronto, New Zealand and NASDAQ. Of particular interest was the resources sector, focusing on both London markets and Toronto.

Closer to home, Wholesale Investor has continued to actively present opportunities to investors.

In August, we partnered with AusBiotech to produce the Life Sciences Showcase 2011. The event brought high growth private and ASX-listed opportunities to 183 attendees. It was a great turnout which highlighted the ongoing investor interest in this sector.

(If you missed the event, or want to refer to any of the companies who were present go to our website to find a number of the presentations. Follow the link to http://www.wholesaleinvestor.com.au/tv.php )

Also online are the presentations from the Emerging Company and Commercialisation Showcase, held in conjunction with the Principal Support Partner Commercialisation Australia. The companies featured at this event represent a significant opportunity for investors as they start to realise the commercial potential of their technologies.

Wholesale Investor is continuing to link investors with opportunities in new ways. We have recently launched a channel partner program giving corporate advisory and finance, private equity and venture capital firms the opportunity to use our unique distribution platform for the benefit of their clients. Anyone interested in learning more about this should contact our General Manager, Kimber Rothwell.

We are also listening to what investors want to see more of in WI. From the survey, respondents told us they wanted to see more private opportunities, access to investor events, small cap ASX opportunities, editorial on private companies and CEO interviews online.

As we continue to expand, we’ll give your more of what you are looking for.

Regards,

Steve Torso - Managing Director, Wholesale Investor Magazine

5

Upcoming Events

Melbourne, Australia

Wholesale Investor Opportunity and Networking Evening

Mongolia Investment Summit

Private Banking & Wealth Management Australia

2nd Annual Australian Microcap Investment Conference

The Mining 2011 Resources Convention

Clean Technology Showcase

Melbourne, Australia

Hong Kong Brisbane, Australia

11 October, 2011 18 – 19 October, 2011

25 - 27 October, 2011 26 - 28 October, 2011

Sydney, Australia Melbourne, Australia15 - 16 November, 2011 28 November, 2011

Wholesale Investor is proud to host the Melbourne Investor Opportunity and

Networking Evening. The Investor Opportunity Evening will provide investors,

brokers, fund managers, and business media with the opportunity to

directly connect with the CEO’s of innovative private, pre-IPO and ASX Listed

companies.

For more information or to register for this event visit www.wholesaleinvestor.com.au

The Australian Microcap Investment Conference is the largest investment

conference in Australia focused on emerging companies.

Hear firsthand from over 20 of Australia’s leading microcap CEOs their

strategies and the market they operate in. The conference will also include

keynote presentations on the economic conditions and market factors

impacting the microcap sector.

For more information or to register for this event www.microcapconferences.com

Building on the success of Hong Kong’s first annual Mongolia Investment

Summit in 2010 and brought to you by the team behind Mines and Money

Hong Kong, the Mongolia Investment Summit returns in 2011, doubling in size

and bringing together even more foreign investors and Mongolian-based

project and companies.

For more information or to register for this event visit www.mongoliainvestmentsummit.com

The Mining 2011 Resources Convention is one of Australia’s most widely regarded

events within the resources industry. The conference will run over three days, on

the 26, 27 & 28 October 2011, at the Brisbane Convention & Exhibition Centre. The

convention will include two auditoriums covering topics such as Metals Outlook,

Funds Management, International Outlook, Exploration in Australia and Junior

Company Presentations. The hub of the conference will be the exhibition area,

hosting 120 companies, showcasing the latest information they have to offer.

For more information or to register for this event visit www.verticalevents.com.au

Wholesale Investor will bring together 12 Private, Pre-IPO and ASX Listed

companies, over 200 investors, brokers, media and industry participants, for

the Clean Technology showcase.

The Showcase is your opportunity to hear live presentations from

12 leadingPrivate, Pre-IPO and ASX Listed Companies in the Cleantech

sectors.

For more information or to register for this event visit www.wholesaleinvestor.com.au

Banking & Wealth Management Australia 2011 is Australia’s leading

conference for Private Banking and Wealth Management professionals. It is

the best conference in the region for Private Banks, Family Offices, Financial

Advisers and other Wealth Managers to hear from the cream of the industry

and gain invaluable opportunities to grow their businesses.

For more information or to register for this event visit www.terrapinn.com/pbw

6

Company Updates

FDA approve Phase II clinical trialViralytics has received allowance from the FDA to conduct a Phase II clinical

trial - the CALM study - of its lead investigational drug CAVATAK™. The trial

is to be undertaken in the USA and will commence later this year. The CALM

study will investigate the effectiveness of CAVATAK™ in the treatment of Late

Stage Melanoma.

Viralytics’ Phase I trials of CAVATAK™ have to date successfully demonstrated

that the product is well tolerated in humans, with minimal adverse side-

effects recorded.

In preclinical studies Viralytics has displayed significant activity of CAVATAK™

in targeting and destroying a wide range of human cancer cells including:

Melanoma, Breast, Prostate, Head & Neck, Glioma (Brain), Lung, Ovarian,

Pancreatic and Multiple Myeloma

Drilling Commences in the Georgina BasinBaraka Energy and Resources Ltd is pleased to announce that the long

awaited drilling program has begun. Baraka’s joint venture partner has been

drilling at their “Baldwin-2” since the morning of Wednesday August 3, 2011.

Although drilling has commenced on our JV partners ground at Baldwin-2, it

is only expected to take three weeks to complete, at which time the rig will

mobilize to Baraka’s EP127 to commence drilling “MacIntyre-2”.

Once drilling has been finalised at these two well sites, MacIntyre-2 will be

the first to be frac’d and completed using multi-stage open hole techniques.

Management believes that the Arthur Creek “hot” shale is potentially

analogous to the Bakken play found in Saskatchewan, Canada and North

Dakota.

Two potential blockbuster drugs in clinical trials Excellent Phase Ib clinical trial results for BNC210 anxiety drug candidate.

Offers dramatic competitive advantages over existing treatments, no

evidence of sedation, memory impairment or addiction.

BNC105 cancer drug trials prove effective against tumours. Highly selective

and potent vascular disrupting agent. Renal cancer trial BNC105 in

combination with Afinitor safe and well tolerated with individual patients >12

cycles treatment. Mesothelioma clinical benefit >25%, one patient showing

57% reduction in tumour measurements. Ovarian cancer Phase I/II trial to

start in 2012.

Merck Serono deal extended. BNO benefits from fully funded R&D, US$47m

milestones per compound, plus royalties

Third Link Growth Fund reweight investmentsAnticipating increased volatility in markets, a reweighting exercise was

undertaken in the lead up to July. From a portfolio dominated by long only

growth positions, the investments were reweighted to decrease exposure to

long-only equities and increase exposure to more defensive asset classes.

Increased exposure to fixed interest, property securities and alternate

investments in the form of long/short equity positions has been the result.

Adopting a more market neutral strategy when markets are choppy can

serve the portfolio well.

“One of the strengths of the Fund is the considerable flexibility in the type of

investments and exposure to each that we may hold,” commented Portfolio

Manager, Chris Cuffe.

All management fees, net of expenses, are donated to the non-profit sector.

7

Company Updates

Forza Capital Working to secure commercial building in MelbourneForza Capital is currently working to secure a large Melbourne CBD

commercial building which will comprise the sole asset of its next

investment offer. The identified property is very well located within the CBD

and has substantial value adding/repositioning potential which should

provide scope for significant improvement in investment yields and capital

values. This is a great opportunity to participate in the strengthening

Melbourne CBD market and obtain exposure to a significant asset. Minimum

investment will be $200k and the investment timeframe is 5 years.

Diamond Energy’s renewable “gen-tailer” model is expanding Diamond Energy’s positioning as renewable/low carbon electricity integrated

“gen-tailer” has been further reinforced through recent milestones.

i. A power purchase agreement has been signed with a new renewable

generator to underpin accelerated growth into Queensland.

ii. Multiple project partners have been notified of successful Government

Grant Applications, to deliver up to 8MW of additional long term

contracted renewable energy.

iii. Above business plan retail customer base growth

Carbon Conscious welcomes carbon farming initiative Carbon Conscious Limited (ASX Code: CCF), welcomes the passage of the

Commonwealth Government’s Carbon Farming Initiative (CFI) legislation

through the upper house of Federal Parliament. Mr. Steve Lowe, Executive

Chairman of Carbon Conscious, said the passage of the CFI legislation

provides additional certainty for investors in carbon bio-sequestration

projects, and creates a mechanism for Australia to become a leading player

in the global carbon economy.

“The CFI provides certainty for the carbon bio-sequestration industry

and confidence for major carbon emitters and investors, who are looking

for proven, reliable ways to offset their carbon emissions. Growing trees

to create carbon credits not only helps reduce carbon emissions, it

converts poor quality land into productive land and generates long-term

environmental, social and economic benefits for local communities.”

Photonz signs with Novasep. $5.4 million raised towards industrial-scale production Photonz Corporation has entered into a development agreement with

Novasep, a world-class provider of purification technology. The agreement

puts the company on track to manufacture the high-value omega-3 fatty

acid, eicosapentaenoic acid (EPA), as an industrial-scale end-product next

year. Novasep was chosen because its production facilities can deliver

pharmaceutical quality and its purification technology will deliver EPA, at

more than 96 percent purity, a key driver to accelerating Photonz’s market

launch. In April this year Photonz signed an agreement with the French

company, under which Separex is developing an industrial process to

concentrate extracts from Photonz’s EPA-rich microalgal biomass. “With

Separex we focus on economic concentration of the omega-3 extract.

We’re now working with Novasep to develop the final process to purify

the concentrate produced with Separex technology,” says Photonz Chief

Executive, Greg Moss-Smith.

8

In Australia, Zork has been manufactured at Scholle’s Elizabeth plant for ``the

past several years’’, said Mr Brooks, who remains with Scholle, along with Zork’s

staff post-acquisition. ``The relationship between Scholle Packaging and Zork

has developed positively over the past several years, with a natural alignment

in industry vision, technology and customer focus,’’ he said.

Scholle’s global wine and spirits director Richard Barrett said the purchase

expanded its closures to bottles as well as its ``key flexible packaging

customers’’. ``The acquisition of Zork is key to Scholle’s customer integrated

packaging business unit,’’ he said. ``We are now able to expand our closure

product by offering to service new and existing customers who pack in rigid

formats, while maintaining the focus on our key flexible packaging customers.’’

Scholle set up its Elizabeth plant in the late 1970s to be close to Barossa

Valley winemakers, expanding to supply food and other beverage industry

customers which now makes up 50 per cent of its business. It employs 250

people in manufacturing, marketing and corporate roles at Scholle’s Asia Pacific

headquarters, Mr De Bono said.

The ZORK company’s first product, conceived by Mr McKenna, was for still wines

and had been successful in export markets.

However, domestic sales for still wine closures have been hampered by the

popularity of the screw cap, now widely used by winemakers in Australia. “The

timing of my new idea appeared to be perfect as the wine industry was getting

really fed up with cork taint and other quality issues and needed a way of

sealing the bottle without spoiling the wine. What I didn’t expect or plan early

enough for was the sudden and massive uptake of the screw cap – a 30 year

old sealing technology that was revived by a combination of clever marketing

by the manufacturers of the screw cap and the support of the ‘technical’ power

brokers in the wine industry – in particular the winemakers and the wine writers.

We soon realised we had lost the war and took a strategic decision to focus our

marketing on Europe and the United States. That decision has proved fruitful

and with the ZORK SPK, we have a “peal and reseal’ solution for sparkling wines

that is unmatched by any other closure globally”. McKenna said.

Zork’s SPK closure for sparkling wines, developed by co-founder and Technical

Director, John Brooks, was given a gold innovation award by the Packaging

Council of Australia in 2009. It is a fully recyclable alternative to the traditional

cork and muselet - the wire cage which holds the cork in place. It is the world’s

first and only commercially proven resealable closure for sparkling wines.

“ZORK SPK’s carbon footprint is 40 per cent lower than cork and muselet, and

featured a foil and gas barrier which prevented flatness and oxidation when the

bottle was resealed” said Mr. Brooks.

Written by Conor McKenna, Managing Director, Twoeyes Adelaide

ZORK, the South Australian wine closure company, has been acquired by the US

owner multinational manufacturer, Scholle Packaging, for an undisclosed sum.

The deal, finalised in May 2011, will allow Scholle to manufacture and market the

ZORK “peel and reseal” stoppers for still and sparkling wine bottles through its

international network of more than 60 countries.

Scholle’s Business Development Manager, Andrew De Bono, said the product

was a good fit for Scholle’s other products for the food and beverage industries,

including its cask wine Bag-in-Box packaging. Scholle founder William Scholle is

acknowledged to be the inventor of the bag-in-box packaging concept in 1947.

ZORK was invented by well-known Adelaide entrepreneur, Conor McKenna in

1999. McKenna conceived the sealing technology, developed the brand name

and identified the market opportunity for ZORK while working in a marketing and

sales role for a major wine bottle manufacturer. He soon after resigned and set

up Twoeyes Venture & Advisory in 2000 to commercialise the technology.

McKenna formed a four-man commercialisation team in 2001 and wrote an

award-winning Business Plan and Business Presentation. Soon after the ZORK

team entered and won the national finals in a Venture Capital competition.

Following their success, McKenna co-founded the ZORK company in 2002 with

team member and industrial designer, John Brooks. $250,000 seed funding for

the fledgling company was put up by McKenna’s mother in Ireland.

From there the ZORK team raised $500,000 from an Angel Investor. This was

soon followed by a $3.3 million investment by a private equity group in Sydney.

Multiple rounds of venture funding and government grants followed over the

next 8 years which allowed them to establish manufacturing and marketing

throughout Australia, Europe and the United States.

8

ZORK seals Scholle deal

9

Investing in unlisted early growth companies at any time is an activity pursued

by investors who have an appetite for excitement, high rewards surrounded by

equally high risks and a strong level of judgment self belief. Being early growth

magnifies the assessment issues for the investor as the enterprise is typically

pre-revenue and balance sheet constricted.

If the economic environment is uncertain, as it is at present, the investment

landscape for this market segment is affected as investor demand cools. The

change is not so great, however, as to make investment into the early growth

company space a ‘no go’ investment zone, but it does make investors more

cautious and more selective about the opportunities they pursue.

So what are the investor criteria in the current market? Well nothing has

changed with the basic criteria, rather the criteria has been refined. The goal

of all investors is to invest in an enterprise with innovative technology, a

strong potential for rapid commercialisation and market penetration, an ability

to protect the market it enters or creates, to have a well considered business

model and an impressive management team.

For an investment to be attractive to an investor it should meet the investor’s

thresholds to the above criteria. But in assessing competing opportunities

what can maximise an investor’s interest in pursuing a particular investment?

The following core elements can only assist:

1. Presentation: to receive a polished, ‘to the point’ elevator pitch or

presentation, ideally made by an engaging spokesperson.

2. Information: all information provided to the investor must be accurate and

correct and reflect both a strong business case and management team.

There is no point presenting documents which present a ‘biased view of

the company. No investor is going to commit significant funds without

Investing in early growth companiesverifying the claims of a company. To some investors, being able to trust

the representations made by the company’s spokespersons is a critical

threshold issue to investing in a company.

3. Due Diligence: for any significant investment due diligence will be required.

The quality of the due diligence is a ‘moment of truth’ for the company’s

representatives. It is through this process that the investor will judge

how well the company is being managed, how well negotiated are its

contracts, how strong and valuable is its IP, how robust is its business

model, business plan and financial models and generally where its

strengths and weaknesses lie.

4. Personnel: to encounter a strong board and strong management team.

Credentialed persons of high calibre who have the right experience and

appropriate expertise are more likely to provide the investor with a higher

level of confidence.

5. Investment Terms: the investment offering terms need to be appropriate. If

the investor is interested in making an investment, then agreement as to

the investment offer terms is usually the most significant discussion and

negotiation point of the process.

The valuing of the investment becomes the most challenging issue. The

resolution of the value aspect of the investment terms is a reflection of

how the parties will relate to each other in the future and therefore needs

to be approached with due consideration.

6. Timing: time is required for an investor to process through the above

items, which can take between 1 and 3 months. The company needs to

respect that time is required for the investor to satisfy their criteria. It also

must be understood that it is not without cost to the investor.

In uncertain times, such as now, investors still look to early growth companies

and focus on the same criteria. Although they are more cautious and selective

with their investment resources, they are still active in assessing opportunities.

For the unlisted early growth company seeking significant funding this is good

news, but there is a need for early growth companies to ensure their business

case is robust and strong and that they present and perform at the top of their

game. It is a challenge that a good team relishes! And investors are attracted

too!

Written by Andrew Ireland and Sarah Thomas Should you have any questions or queries or suggestions, please do not hesitate to contact any of our commercial and corporate team including Andrew Ireland, Principal - aireland@argylelawyers.com.au; and Sarah Thomas, Lawyer sthomas@argylelawyers.com.au

10

Executive SummaryMesynthes is a soft-tissue reconstruction company using its proprietary Endoform technology

to develop regenerative tissue substitutes for reconstructive surgery and wound care.

These markets represent an opportunity in excess of US$1B.

Mesynthes gained marketing clearance from the United States FDA in January 2010 for

Endoform™ Dermal Template for acute and chronic wounds. In March 2011, the company

secured a North American marketing and distribution agreement with a major healthcare

multinational for their first Endoform based product and they have also entered into

a development agreement with another major wound care multinational. A specialised

manufacturing facility operating under a quality management system was commissioned

in early 2011.

Competitive Advantages• Compared to established market offerings Endoform™ is a shelf-stable tissue substitute with:

• Authentic structure, signals and substrates of the native extracellular matrix

• Quantifiably superior blood vessel in-growth

• Complete remodelling and replacement by the patients’ own tissue over time

• Clinical outcomes in diabetic and venous ulcers studies which are very encouraging (n>50)

• Excellent strength and handling characteristics

• Three year shelf life at ambient temperatures

• Pipeline developments for implantable products and potential for delivery of cells,

antimicrobials and bio-actives

Key Investment Highlights• Sustainable competitive advantage, in large growing markets

• Platform technology supports development of multiple high-value products. The first product

will launch in 2011 and one further product is expected to launch in 2012

• Technology and regulatory risks addressed

• World leading team with experienced Board, Advisory Board and Investors - Management

team have in excess of 60 years of combined experience in the life sciences sector.

The Board of Directors has extensive international commercial experience and the Clinical

Advisory Board is comprised of leading United States based clinicians and academics.

Mesynthes has been backed by New Zealand’s premier early-stage investors

• Secured partnerships with multinational companies

• Demonstrated capability to achieve significant results with limited resources. To date,

the company has raised $4M from private investors

Board & Management:

Brian Ward - CEO BVSc MRCVS MBA(dist) Brian Ward has held senior roles in life science companies over the last 20 years.

Nancy Yopp - Director OperationsBS, MBANancy Yopp has over 25 years of technical, manufacturing and operations experience in the US medical device industry.

Barnaby May - Director Research PhDBarnaby May has an extensive research and development experience in academia and industry.

Phil McCaw - ChairBBSPhil McCaw is a qualified chartered accountant and has served on the Boards of numerous early stage companies and is an active angel investor.

Corporate StructureMesynthes is a New Zealand registered private company.

Exit StrategyA number of exit options exist for investors over the next 2-5 years including:Acquisition by a major medical device company, a merger with an established company with complimentary technology or marketing channels,

or an IPO on a suitable public exchange.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Mesynthes Ltd.

BIO TECH

Mesynthes Ltd

Medical Device

2007

Early stage

Wellington, New Zealand

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

11

Benitec Limited (ASX:BLT)

Biotechnology-therapeutics

1997

Early Stage

Sydney

Company Name

Sector

Year Established

Business Stage

Location

BIO TECH

Executive Summary Benitec Limited is a publicly listed (ASX:BLT) biotechnology company developing novel

human therapies based on a transformational gene silencing technology, DNA-directed RNA

interference (ddRNAi). Benitec holds the predominant patent position in the use of ddRNAi

for human therapeutics, with an exclusive, irrevocable, world-wide license to CSIRO’s patent

estate by generating double stranded RNA inside a cell from a DNA construct. Benitec

collaborates with groups globally to develop novel therapeutics for chronic life threatening

diseases and disorders, particularly in cancer and infectious disease. Benitec’s current projects

are directed to using gene silencing in lung cancer, intractable cancer-associated pain, and

hepatitis B infection.

Competitive Advantages• Cancer-associated neuropathic pain. The program is aimed at developing a ddRNAi-based

therapeutic to silence genes in the spinal cord involved in mediating intractable pain.

• The non-small cell lung cancer program, in collaboration with the University of New South

Wales. Researchers at UNSW have shown that using ddRNAi to silence the beta III tubulin

gene can significantly overcome the resistance of lung cancer cells to chemotherapy drugs.

These programs are fully Benitec funded programs. It is anticipated that these programs will

enter Phase I clinical trials in 2012.

• The hepatitis B program is developing a ddRNAi-based therapeutic targeting a key HBV gene.

Partnered with Biomics Biotechnologies Co, Ltd in China.

Key Milestones & Investment Highlights• Exclusive irrevocable worldwide rights to a platform technology with huge market potential in

human therapy: ability to permanently silence any gene associated with a disease or

condition

• Dominant global position with robust intellectual property, including successful

re-examination in all major jurisdictions worldwide. Over 30 patents granted internationally.

• Broad portfolio of targeted therapeutics – neuropathic pain, lung cancer and hepatitis B

• Building value through licensing of therapeutics and technology

• Financially strengthened by recent successful $8M funding via a renounceable rights issue

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search forBenitec.

Board & Management:

Peter French - CEOBSc, MSC, MBA, PhDCell and molecular biologist. Principal Scientist - Centre for Immunology, St Vincent’s Hospital; Founder of Cryosite (CTE); Ex-President ANZSCDBI.

Peter Francis - Non-Executive ChairmanLLB Grad Dip (Intellectual Property)Partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology. He is a legal specialist in the areas of intellectual property and licensing.

Mel Bridges - Non-Executive DirectorBAppSc FAICDMore than 30 years experience in the global biotechnology and healthcare industry. Chairman of Alchemia Limited, Impedimed Limited and Leaf Energy Limited. He also co-founded the listed company Panbio Ltd. Tissue Therapies Limited. The Queensland Entrepreneur of the Year in 2004.

John Chiplin – Non-Executive DirectorPh.DFormer CEO of Arana Therapeutics (acquired by Cephalon). Former head of the $300M ITI Life Sciences investment fund in the UK. Owns Newstar Ventures Ltd.

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX :BLT

21,305,772

$0.0230

0.0520

0.0210

Share Information As at 6 September 2011

ASX:BLT 6 month price chart

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

0.04

6080

4020

0.02

0.03

12

BIO TECH

Executive SummaryEastland Medical Systems Ltd (EMS) is an Australian based Biotechnology licensing company.

Our focus is the identification, in-licensing and value adding to new or novel applications

of existing medicines. This strategy results in a greatly de-risked project portfolio. EMS adds

value by managing the development program. Our revenue model is based on out-licensing or

trade sale of the asset. Our current lead project is ArTiMist™ a sublingual (under the tongue)

anti-malarial for the treatment of childhood malaria.

Current Projects• Current lead project is ArTiMist™, a sublingual (under the tongue) anti-malarial for the

treatment of childhood malaria that contains the anti-malarial compound Artemether,

a well-established drug for the treatment of malaria

• EMS has the licence for Africa, Asia, India and the Pacific regions, an area that contains about

97% of the world’s malaria cases

• The preliminary raw data and observations from the current Phase III ART004 clinical trial

continues to confirm earlier results from the Phase II ART003 trial and provide a convincing

argument for sub-lingual delivery of Artemether for the treatment of childhood malaria

• Anecdotal reports from the medical staff and observers coupled with the clinical data show

greater than 90% parasite reduction within 24 hours and comatose children soon sitting up

in their beds

Key Investment Highlights• Completion of current 150 patient Phase III Randomised, Open Labelled, Active Controlled,

Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children with Severe

or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria with Gastrointestinal

Complications. Due for completion 3rd quarter 2011

• Out Licensing/Trade sale of ArTiMist™ project. EMS have had preliminary interest from

a number of groups

• Eastland’s wholly owned subsidiary, Westcoast Surgical and Medical Supplies are continuing

to aggressively target new business, EMS believes that there will be a number of highlights

from this area during the next 12 months

• Identification and in-licensing of a follow on project. We are actively sourcing new

opportunities to follow on from ArTiMist™

Eastland Medical Systems Ltd

(ASX:EMS)

Biotechnology

2001

ASX Listed

Western Australia

Company Name

Sector

Year Established

Business Stage

Location

Board & Management:

Peter Jooste QC - Non-Executive Chairman Peter Jooste was appointed Queens Counsel in 1997 and practises principally in corporations law, particularly schemes of arrangement and reconstruction. He was an inaugural member of the Takeovers Panel and a former President of the International Business Council in WA and has acted in numerous takeovers, mergers and acquisitions.

Michael Stewart - Non-Executive DirectorMr Stewart has a broad corporate and management background with a strong understanding of the financial markets. Mr Stewart has been extensively involved in bilateral donor funded and World Bank co-financed Aid Projects in under-developed countries.

Stephen Carter - Chief Executive Officer/Executive DirectorMr Carter has extensive pharmaceutical industry experience and has held a variety of senior positions with listed and unlisted public companies, including roles as Chairman and Managing Director. He has extensive contacts and experience in the financial markets and the pharmaceutical industry.

Share Information

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:EMS

11,293,488

$0.0190

0.0740

0.0160

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Eastland Medical Systems Ltd (ASX:EMS).

As at 6 September 2011

ASX:EMS 6 month price chart0.04

0.03

0.03

0.02

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

6080

4020

13

Jubilent Health Aust Limited

OTC medicines

4

Market ready

Australia

5 mil equity to scale

Company Name

Sector

Year Established

Business Stage

Location

Seeking

BIO TECH

Executive Summary Jubilent Health Aust. Limited is poises for rapid growth and is inviting investors onboard in

order to fund the scaling up of proven existing business and expansion of the unique product

range to sell into existing and new pharmacy customers and begin the global expansion of it’s

brands.

Jubilent Health Aust. Limited, an Australian Pharmaceutical company, has unique patented

technologies resulting in formulae’s and API’s (Active Pharmaceutical Ingredients) which will

change the way many medical conditions and diseases are treated. Conditions like Obesity,

Diabetes, High Cholesterol, and even male infertility will be treated by medicines produced by

Jubilent, by targeting fundamental cellular mechanisms to reverse symptoms at their origins

and so reverse diagnosis.

Jubilent Health Aust. Limited will continue to manufacture products with lots of market “Sizzle”

like ToneUP® the world’s first ‘Body Composition Change Product’, already proven in the

Australian market place to be capable of generating Gross profits in excess of $10million if

marketed nationally and clinically proven in university trials to reduce fat and increase muscle

mass without change in diet or exercise.

Competitive Advantages• API’s (Active Pharmaceutical Ingredients)

• Unique diagnosis reversing medicines.

• Strong Pipeline of products

• Paradigm shifting treatment options

• Multiple distribution channels established

• Real market experience, back robust projections

• Strong management team with proven record

Key Investment Highlights• Rapid growth with good market uptake achieve already

• High margin products in a high growth sector

• Revenues achieved in the first year

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search forJubilent Health.

Board & Management:

Norman Ohl - Director/ Company SecretaryNorman is the founder of Jubilent Health Aust. Limited and brings a wealth of management and entrepreneurial acumen to the Company. Long track record of high growth high value business

Peter Degnian - DirectorB.PharmPeter has been a registered pharmacist since 1983 and still active in retail and patient interaction

Cathrine Dahlgren - DirectorM.AppSc (App Chem), Dip. Bus (F’line M’ment)This vast experience, including work with Sigma Nutraceuticals/Herron Nutraceuticals, Progen , Mediherb, provides solid regulatory expertise to the Compan.

Mario Gattino - DirectorApp Sc( Med Admin), MBA ( Exec), Dip Bus (M’ment)Mario Gattino is a former global VP level senior executive with Pfizer Inc., the world’s leading biopharmaceutical company, with extensive international experience.

Corporate StructureAustralian Public Company

Exit StrategyJubilent Health hopes to list on a suitable exchange at an appropriate time.

14

Executive SummaryGlobal Kinetics Corporation (GKC) provides point of care measurement and reporting of

Parkinson’s disease (PD) motor symptoms for neurologists and professional carers to manage:

• Surgical and pharmacological interventions to treat dyskinesia;

• Routine pharmacological treatment of bradykinesia and dyskinesia; and

• A means for patients to manage their therapeutic compliance.

Adoption of the PKG System will result in better patient clinical outcomes, lower patient

management costs and a better quality of life for PD patients. The addressable market in

Europe, US and Australia is $345M+ which represents only 20% of the 12M+ people forecast to

have PD by 2015. The company forecasts annual revenue of $20M+ and NPAT of $8M within the

five years.

Competitive AdvantagesGKC’s core intellectual property is founded on sophisticated software that differentiates

clinically important movement from normal movement and reports this as a bradykinesia and

dyskinesia score.

This intellectual property is protected by:

• Patent;

• Unique domain expertise of the GKC team;

• Retaining data management services in-house limiting access to GKC’s proprietary

algorithms and data library; and

• Investing in ongoing research and development alone and in partnership with the Howard

Florey Institute.

Key Investment Highlights• Solving a significant unmet need in the management of PD;

• A large and growing global market;

• Unique and defendable intellectual property;

• Regulatory approval in Australia, United Kingdom and Europe;

• Engagement with key industry stakeholders;

• A team that has a proven record of delivering value for shareholders.

Board & Management:

Dr David Fisher - Director 1st Class Honours Rural Science; PhD Chemical Engineering; Masters in Applied Finance and InvestmentsDavid is a founding Venture Partner with Brandon Capital Partners. David was CEO of Peptech Limited. Prior to Peptech, David spent ten years with Pharmacia AB (now part of Pfizer, Inc). David is a past president of the Australian Biotechnology Association and past chairman of the CSIRO’s Division of Animal Production Industry Advisory Committee.

Andrew Maxwell - Managing DirectorMBA, MAcc, ACPA, MAICDAndrew has a proven track record of entrepreneurial business success in Australia and Asia spanning over 25 years. Andrew is the former CEO of ESCOR Private Equity (a Smorgon Family Company). Prior to joining ESCOR, Andrew was a serial start-up company entrepreneur with a history of successful company launch, business growth and exit.

Corporate StructureProprietary Limited Company.

Exit StrategyThe exit plan for investors is via a listing on an appropriate exchange or a trade sale.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Global Kinetics.

MEDICAL DEVICE

Global Kinetics Corporation

Medical Devices

2007

Commercialisation

Melbourne

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

15

BIO TECH

BioDiem Ltd (ASX:BDO)

Biotechnology

2004 (IPO)

Commercialisation

Melbourne

Company Name

Sector

Year Established

Business Stage

Location

Executive SummaryBioDiem is a vaccine company developing vaccines for both treatment and prevention of

disease. The leading technology is the LAIV (Live Attenuated Influenza Virus) which was

launched in India in July 2010 as an intranasal vaccine for prevention of swine ‘flu. The LAIV is

also in development for seasonal and other pandemic influenzas. Sales from these products

would generate royalties for BioDiem. The first royalties flowed in 2010. BioDiem is also

developing the LAIV for use in non-influenza vaccine design to produce vaccines for cancer

and infectious diseases. BioDiem intends to generate income from sale of licences to other

vaccine manufacturers for use of the LAIV vaccine design system.

Current Projects• Successful commercialisation of the LAIV technology (launch of Nasovac™ in July 2010)

• In-house vaccine development skills to expand LAIV uses

• GMP materials available for LAIV development (virus and cell bank)

• LAIV induces a broad immune response - mucosal, systemic and cell-mediated responses

• High yield manufacture in egg & cell-based production - to meet pandemic need

• Extensive clinical trial and on-market experience (100m doses) in Russia (egg-based)

vaccine has established efficacy and safety

• Intranasal delivery eliminates need for needles and trained personnel

• Cell-based production provides advantages in bird (avian) flu outbreak when egg supply for

standard flu vaccine production could be compromised.

Key Milestones & Investment Highlights• Global market size in 2009: US$22.7b (US$36.5b in 2013)

• High growth market: CAGR 2008-2013: 13%

• There remains a high level of unmet medical need - >40 human disease pathogens without

effective vaccines

• High barriers to entry with little generic competition

• LAIV pandemic influenza applications already marketed and generating revenue

• First launch of LAIV based vaccine (Nasovac) for pandemic H1N1 (swine flu) in Indian market

in 2010. Royalty payments from sales into private sector commenced.

• LAIV vector project commenced to maximize value of asset.

• LAIV vector applications aim produce early revenue via research and commercialisation

licences.

Share Information

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:BDM

9,133,080

$0.0900

0.2000

0.0790

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for BioDiem .

As at 6 September 2011

ASX:BDM 6 month price chart

0.15

0.20

0.10

0.05

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

0.60.8

0.40.2

Board & Management:

Hugh Morgan AC - ChairmanLLB, BComHugh Morgan is Principal of First Charnock. He is a member of the Lafarge International Advisory Board; an Emeritus Trustee of The Asia society New York; Chairman Emeritus of the Asia Society AustralAsia Centre; and President of the National Gallery of Victoria Foundation.

Julie Phillips – Executive Director & Chief Executive OfficerBPharm, MSc, MBAMs Phillips was appointed to the position of Chief Executive Office on July 1, 2009 and was appointed a director on May 7, 2010. She has worked as the CEO and director of start-up Australian biotechnology companies in the life sciences sector.

Larisa Rudenko - DirectorMD, PhD, DScProfessor Rudenko is Head of the Virology Department in the Institute of Experimental Medicine, St. Petersburg, Russia. She is recognised as one of the world’s leading experts in live attenuated influenza vaccines.

16

Executive SummaryGold Coast Accident & Medical Clinic (A&MC) is a private emergency clinic designed to take

direct pressure of the public system. The model is designed to allow walk in and ambulance

access to services providing comprehensive treatment solutions with an attractive pricing

strategy compared to private hospitals. There is also a general practice imbedded in the model

to ensure coverage of a wider range of patients to capture diverse revenue streams. This

delivers a model with an end to end treatment solution for clients.

Competitive Advantages• Significantly shorter waiting time for patients compared the public system

• Price point attractive alternative to private hospital emergency departments

• Focus on emergency treatment provides a niche & high degrees leverage with the

community & state governments

• Model can be replicated in every jurisdiction in Australia

• No direct competition. Many general practices will do some emergency treatment, however

not a focus like the A&MC model

• Model can utilise diverse healthcare workforce: Doctors, Nurse Practitioners, General

Practitioners & nursing assistants

• Opportunity to provide specialist services, such as Nurse Practitioner procedural clinics to

add value to the business & client experience

• High profile through strategic sponsorships with sporting clubs

Key Investment Highlights• Opportunity is strong for public/private partnerships

• Strong revenue forecast

• Branding has commenced & is able to be rolled out nationally

• Develop specialist clinics using Nurse Practitioners, for example pain management &

endoscopy clinics

• Specialist clinics will attract strong rebates from Medicare & private insurers

Board & Management:

Rod Wyber-Hughes - DirectorRod has worked all over Australia as a Remote Area Nurse in isolated Aboriginal communities; he managed workforces across large geographical areas. Headed up the second phase Commonwealth health intervention in the NT.

Tracey Wyber-Hughes - Operations Manager, Risk ManagerTracey has over 23 years of international nursing experience, working in diverse settings ranging from cutting edge HIV clinics to Remote Area Nursing.

Corporate StructureWH Medical Pty Ltd is wholly owned by the director Rod Wyber-Hughes. WH Medical Pty Ltd owns 100% of the shares in Updown Nominees trading as Gold Coast Accident & Medical Clinic.

Exit StrategyExpand the model to other locations and seek a trade sale.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for WH Medical.

WH Medical Pty Ltd

Health Care

2009

Expansion

Gold Coast, Queensland

$2 million

Company Name

Sector

Year Established

Business Stage

Location

Seeking

MEDICAL DEVICE

17

BIO TECH

Executive SummaryPhylogica is engaged in the discovery and development of novel peptide-based

biopharmaceuticals. Phylogica enters into discovery alliances with large Pharmaceutical

companies for which it identifies potent bioactive peptides. These deals provide access to

short term revenue as well as future milestone payments and royalties.

Phylogica has discovered and validated a proprietary class of targeted peptide therapeutics

(Phylomers®) which constitute the most structurally diverse source of peptides available.

Phylogica has made libraries of billions of Phylomers from which drug candidates can be

selected using the company’s advanced screening methods. Phylogica owns this unique

class of peptides, with 16 patent families, including multiple granted patents in the US and

Europe. Phylogica is in the commercialization phase and is beginning to sign discovery deals

with some of the world’s largest pharmaceutical companies, including Roche, MedImmune

(biologics unit of AstraZeneca) and Pfizer.

Competitive Advantages• Advantages over biologics discovery platforms (antibodies, protein scaffolds or random

peptides)

• Phylomer libraries are the most structurally diverse biologics libraries available

• The hit-to-target ratios from Phylomer® libraries are high and the proportion of hits which are

of high target affinity, and are biologically functional, is also high

• Phylomers can be straightforwardly made by chemical synthesis

• Phylomers can be delivered by patient friendly means such as intranasally

• Phylomer libraries (unlike antibody libraries) are not associated with patent ‘royalty stacks’

Key Milestones & Investment Highlights• Phylomers offer clear advantages over competing biologics drugs

• Phylogica has validated its technology and streamlined its processes to allow scalability

• Phylogica has signed drug discovery partnerships with three leading Pharma companies since 2009

• Phylogica and Roche extended their collaboration in May 2011 following initial success

• Phylogica is in discussions with multiple Pharma companies and expects more deals over

next 12 months

• Unlike most Australian biotechnology companies, Phylogica bears no risk from failure in

clinical trials since its candidates are licensed at the discovery stage to partners

• Phylogica’s strategy is driving near-term revenue growth and accelerated cash sustainability

• Phylogica’s peers are valued at more than US$100 million

• The average acquisition value for a drug discovery company like Phylogica is hundreds of

millions of dollars

Board & Management:

Dr Doug Wilson - Executive Chairman MB, ChB, PhD, FRACP, FRCPAFormally Global Head of Medicine Boehringer Ingelheim. Oversaw regulatory approval and launch of 10 drugs.

Professor Paul Watt - Executive Director/CEO BSc. D. Phil (Oxon)Doctorate from Oxford, Postdoctoral Fellowships at Harvard and Oxford; 40 publications, 19 patents.

Nick Woolf - Executive Director/CFOMA (Oxon), FCCA18 years experience in the industry, equity research and investment banking. Formerly Chief Business Officer and Executive Director of Oxford BioMedica. Previously, he was Head of European Biotechnology Research at ABN Amro and he has held similar roles.

Bruce McHarrie - Non-Executive DirectorB.Com FCADirector, Finance/Business Development, Telethon Institute for Child Health Research. Former roles: Assistant Director Biotech Division, Rothschild Asset Management, London, Coopers&Lybrand, Deloitte.

Share Information

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:PYC

25,932,630

$0.0640

0.0890

0.0420

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Phylogica Limited (ASX:PYC).

As at 6 September 2011

ASX:PYC 6 month price chart 0.08

0.07

0.06

0.05

30

2010

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

Phylogica Limited

(ASX:PYC)

Biotechnology and Pharmaceuticals

2003

Commercialisation

Perth, Australia

Company Name

Sector

Year Established

Business Stage

Location

18

Executive SummaryPhotonz is a world-leader in the production of the omega-3 compound “EPA” by fermentation

for high purity, pharmaceutical applications.

Demand for EPA is growing exponentially but the world’s supply is extracted from wild fisheries

that are a variable and risky source. Photonz avoids these supply risks and makes EPA “like

beer” that is economic to purify to pharmaceutical concentration.

Photonz will sell EPA to manufacturers of regulated pharmaceuticals making products for the

cardiovascular disease drug market – specifically, treatments for dyslipidemia (high blood

cholesterol and triglycerides).

The Company is currently completing process development at pilot industrial scale and

expects to begin product sales in 2012.

Competitive Advantages• Sustainability – Photonz’ process uses simple industrial commodity inputs and is not

dependent on the continuing viability of wild fisheries or affected by natural variability or

environmental change.

• Security – Pharmaceutical quality management systems can be applied over the entire

Photonz process chain (unlike fish extract product) and multiple independent manufacturing

sites can be established.

• Consistency – Independence from the natural variability of wild fisheries and the application

of pharmaceutical quality management systems throughout the manufacturing process

ensure a consistent product.

• Proprietary process – Patents have been applied for critical elements of Photonz’ process

and intermediate products.

Key Investment Highlights• Proprietary manufacturing technology with freedom to operate.

• Validated manufacturing technology, December 2011.

• Sales late 2012.

• Market need for EPA in established cardiovascular disease (high cholesterol) market.

• Growth market - exponential growth in demand for EPA.

• Exposure to drug markets but lower technical & commercial risk.

• Excellent management team with prior relevant success.

Board & Management:

Greg Moss-Smith - CEOMSc, MBA, IP LawFormer Global Sales Director Novozymes Biopharma. Former VP Commercial Operations GroPep Ltd (ASX:GRO)Director NZBIO

Richard Justice - CFOBCom, MBA, ACA, CMA, ACISFormer CFO Living Cell Technologies (ASX:LCT). Former COO Brocker Technology Group (NASDAQ:BKI)

Doug Wilson - Director MB, ChB, PhD, FRACP, FRCPAExec. Chair Phylogica LtdFormer Head of Worldwide Medical Research, Boehringer Ingleheim

David Kyle - AdvisorBSc, PhDCo-Founder of Martek BioscienceFormer Head of R&D Martek Bioscience

Corporate StructurePrivate, New Zealand Company .33 Shareholders. 71% owned by four holdings.

Exit StrategyPhotonza Corporation hope for a trade sale but may list on a suitable exchange at an appropriate time prior to acquisition.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Photonz Corporation Limited.

BIO TECH

Photonz Corporation Limited

Pharmaceuticals

2002

Late pre-revenue

Auckland, New Zealand

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

19

MEDICAL DEVICE

Xenexus Pharmaceuticals Pty Ltd

Biotech/Pharmaceuticals

2008

Early stage

Sydney

Development Capital

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive SummaryXenexus is undertaking R & D on existing drugs in new indications to secure new use patents

on these re-profiled drugs. The company focus is on:

• Japanese pharmacopeia – drugs only ever registered in Japan

• Drugs with good safety profiles

• Unmet medical needs in large markets

• Low complexity trial requirements

• In-vivo studies and Phase IIa trials where relevant

• Pharma partnerships and out-licensing at early Phase II trial stage

• VC and grant financing where appropriate for each project

Competitive AdvantagesXenexus Pharmaceuticals is pursuing a low risk, low cost business model:

• Xenexus has access to some of the best labs in the world to do low costs animal studies

• Leading scientists in their field who have developed “gold standard” drugs are on the

Xenexus Scientific Advisory Board and are shareholders in the company

• Xenexus drugs have know safety profiles, which dramatically increases the likelihood of

Xenexus re-profiled drugs reaching the market

• Low cost and complexity Phase IIa trial requirements

• Small experienced team, having previously built Nuon Therapeutics Inc

Key Investment Highlights• A proven management team

• An outstanding Scientific Advisory Board

• A low risk, low cost Business Model

• A successful track record with Nuon Therapeutics

• Positive in-vivo data in XEN-101 gout, with patent lodged

• Chronic gout is an unmet medical need

• Positive in-vivo data XEN-102 multiple sclerosis with patent being lodged

• MS an unmet medical need

• XEN-102 is anti-inflammatory and likely neuroprotective

• Two additional programs currently at in-vivo screening stage

Board & Management:

Dr Michael L Selley - Chief Executive OfficerPh.DPreviously the Founder and Chief Scientific Officer for Nuon Therapeutics. Academic at the John Curtin School at ANU.

Prof Sir Marc Feldmann - Director and Member of the Scientific Advisory BoardM.B., B.S., Ph.D., FRCPath, FRCP, FMedSci, FAA, FRSProf Steinman is head of the Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College London.

Professor Larry Steinman - Member of the Scientific Advisory BoardB.A., M.DProfessor, Departments of Neurology and Neurological Sciences, Stanford University

Jay Hennock - Chief Operating OfficerB.EcWorked in corporate advisory with Citibank and Bank of America. A founding shareholder and CFO of Nuon Therapeutics.

Corporate StructureXenexus Pharmaceuticals is a NSW Registered private company.

Exit StrategyXenexus aims to list on a suitable exchange at an appropriate time, or pursue a trade sale.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search forXenexus Pharmaceuticals.

20

Executive SummaryOur objective is to grow a consumer health company by developing or acquiring high potential

brands or products and selling them through retail and online channels. Our brands can be

summarised as follows:

Herb Valley : Well established range of supplements and personal care products sold

exclusively through the health food channel.

Activecare : Developing range of pharmacy only complementary medicines

Activelife : An open brand of personal care products including a Paw Paw Lip Balm and

Aluminium Free Deodorants and Anti-Perspirant.

Sports-haler : Innovative medical device for the delivery of Ventolin and Asimol.

Stay-Healthy : A wholly owned subsidiary established to develop direct to consumer online

and catalogue sales.

Competitive Advantages• Core of innovative and unique products

• Low cost base

• National sales team

• Established customer base and distribution network

Key Investment Highlights• Sales growth 444.76%

• Customer growth 151.96%

• Acquisition of Herb Valley

• Acquisition of Sports-haler

• Launch of Activelife personal care range

• Launch of Chia Seed Oil & Natralgesic Complementary Medicines

• Development of brand and Stay Healthy Club web sites

• Re-packaging and positioning of Herb Valley

Board & Management:

Joe Bayer - ChairmanBBus (Acctg) CPA MAICDFormer Executive General Manager, Mayne (Faulding) Pharma Asia Pacific and Mayne Consumer Products.

Geoff Crittenden - Managing DirectorBSc(Hons)Eng CengAn experienced entrepreneur who has held senior executive appointments in Australia and overseas.

Rakesh Raj - DirectorMBA BSc EngSenior pharma executive former Director Pharmacy Division, Sanofi-aventis and GM Sales Sandoz.

Craig Stokoe - DirectorMD of LPN, a leading marketing and design consultancy.

Exit StrategyTo grow sales to more than $10 million within the next five years and look for trade sale or buy-out opportunities.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Cynergy Health.

BIO TECH

Cynergy Health

Consumer Healthcare

2008

Development

Sydney

Company Name

Sector

Year Established

Business Stage

Location

21

Executive SummaryEstablished renewable/low-carbon electricity integrated “gen-tailer” seeking to accelerate

expansion. The business has a “portfolio” generation strategy, operating its own and 3rd

party generation; these integrate with its licensed electricity retailing through channels that

deliver contracted customers. In addition “Diamond CLEAN” delivers a highly attractive power-

purchase alternative for large generators. The business is seeking to accelerate its expansion

in response to strengthening drivers including energy/carbon policy reform, technology cost

reductions, and changing customer preferences. This provides an opportunity for investors

to participate in an established visionary business positioned in the new energy low carbon

economy.

Competitive Advantages• Operating renewable generation assets supported by long term contracts

• Integrated “gen-tailer” model provides attractive returns through spread & risk management

• Power purchasing agreements with third party renewable generators to balance with retail

consumption

• “Diamond CLEAN” a highly attractive power-purchase alternative

• Integrated CRM/Billing System is operational and scalable, linked to customer smart metering

& supports in-home technologies.

• Strong relationships and credibility with government and renewable project partners

• Company Directors & Management are highly skilled & experienced across commercial,

engineering, generation, network & energy market & demonstrated track records of delivery.

Key Milestones & Investment Highlights• Commissioned Tatura Biogas plant (2007) and Shepparton Biogas plant (2009)

• Obtained Victorian retail electricity license (2007)

• Secured Lend Lease Ventures investment (2008)

• Over 3,500 solar installations throughout Australia delivered (2009-10)

• Sold rights to Victorian Wave farm (2009) ( still maintains PPA rights)

• Obtained SA, NSW, and QLD retail electricity licenses (2010)

• Integral partner in UN World Environment day “Virgin Blue Business - Best Environmental

Business Initiative” (2010)

• Launched Diamond CLEAN (2010)

• Shortlisted Participant in multiple Government Grant Applications (2011)

• Trademarks registered to Diamond Energy, Diamond Energy Advantage and Commercial Green

• Awarded $1.5 m by Victorian Government and establishes 50/50 JV Colac Power Company

(2010)

Board & Management:

Anthony Sennitt – Chairman and Managing DirectorBSc, BEng (Chem), MMT, Dip. Fin. Services Professional experience in the global energy markets for over two decades. Experience built through a vari-ety of major roles at global energy corporations, based in Australia and Singapore.

Mark Bertoncello – Chief Investment Officer BEng (Hons) MBA, Melbourne Business SchoolExtensive renewable energy experience plus executive management in Australian listed company and adviser in global professional services firm.

John Chiodo – Chief Operations OfficerBEng (Hons) Grad Diploma Applied Finance (FINSIA)Over 15 years experience in the development of a range of clean, renewable and distributed generation technologies.

Corporate StructureDiamond Energy is a medium sized Australian owned private company with 100% owned subsidies and a range of shareholdings in generation companies

Exit StrategyThe proposed exit strategy for investors is via a listing on a suitable exchange or a trade sale at an appropriate time.

Further InformationTo learn more about this opportunity, go to www.wholesaleinvestor.com.au and search for Diamond Energy.

Diamond Energy

Clean Tech/ Retail

2004

Expansion

Victoria

Pre IPO funding

Company Name

Sector

Year Established

Business Stage

Location

Seeking

CLEAN TECH

22

Current ProjectsProject 1: Little Takas nappies and Bamboo baby wipes – Australia

EcoQuest launched the Little Takas nappies and Bamboo baby wipes range

in Australia in October 2010. The products are now stocked in over 300 retail

stores across Australia, including Toys R Us, Baby Kingdom, Franklins, and a

growing number of IGA stores, promoted and sold through 4 leading nappy

e-tailers and on its own e-commerce website www.littletakas.com.

Project 2: Little Takas nappies and Bamboo baby wipes – UK and US

EcoQuest has launched the Little Takas nappies and Bamboo baby wipes range

in the UK, focusing initially on internet sales such as resell through the website

of the UK’s largest parenting charity for parents the National Childbirth Trust

(NCT) www.nct.org.uk. The company will approach US brokers in Q4 of 2011.

Project 3: Little Takas nappies and Bamboo baby wipes - Asia

From July 2011, Ecoquest entered the Asian market. The Little Takas range is

sold in three different Hong Kong supermarket chains including Three Sixty

(Hong Kong’s largest organic and natural food store), Marketplace (a high

end supermarket chain) and Wellcome (Hong Kong’s longest established

supermarket chain). The company plans to expand into other Asian countries.

Competitive Advantages• EcoQuest addresses a major growth market - as major contributors to landfill,

disposable nappies represent one of the world’s biggest environmental

problems, taking over 100 years to break down. The Little Takas nappies and

Bamboo baby wipes ease consumer consciences but fit into modern

lifestyles.

• EcoQuest has a highly experienced team, including global eco-nappy and

consumer sales experts

• EcoQuest has technology that is proven by both rigorous consumer testing

and meets stringent industry standards

• Ecoquest is already engaged in developing a second generation nappy which

will increase its use of sustainable materials whilst retaining its

biodegradeable credentials

• EcoQuest is listed on the ASX, and therefore provides both the potential for

excellent capital gain, and the flexibility of sale of shares through the ASX

Executive SummaryEcoQuest Limited, the clean technology company developing biodegradable

disposable personal care products from sustainable sources, has started

to realise its global market strategy with the Little Takas 90% biodegradable

nappies and 100% biodegradable bamboo wipes range on sale in a growing

number of retail and e-tail stores in the UK, Asia and Australia as well as through

its own website www.littletakas.com.

The company is in talks with major Australian retail chains and is conducting a

strong marketing and PR campaign across print, broadcast, online and social

media to increase awareness and drive sales.

The company wants up to 5% market share of the total Australian nappy market

and plans to grow the eco market and become the eco-nappy of choice for

Australians based on its superior sustainable content, higher total product

biodegradability, better performance, better margin to retailers and lower retail

price (in its segment).

The Australian eco nappy market is expected to grow by more than 25% per

annum. The company’s mission is to create a globally recognised brand of

biodegradable personal care products based on proven and tested principles of

sustainability.

The company will also continue developing and protecting its intellectual

property, while refining and growing its product range.

EcoQuest Ltd

(ASX:ECQ)

Cleantech

2007

Trading

Western Australia

Company Name

Sector

Year Established

Business Stage

Location

CLEAN TECH

Share Information

ASX:ECQ 6 month price chart

0.06

0.04

0.02

0.6

0.4

0.2

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:ECQ

3,641,287

$0.0290

0.1050

0.0240

As at 6 September 2011

23

Key Milestones & Investment Highlights• September 2010 - 1st order (1m units) Little Takas nappies distributed to

independent supermarkets

• October 2010 – Official product launch of Little Takas nappies and Bamboo

Baby wipes

• December 2010 – product stocked in 249 stores across Australia

• January 2011 – 2nd order (2m units) arrives in Australia

• January 2011 – new Little Takas website with global e-commerce functionality live

• February 2011 – first revenue deposited

• May 2011 – UK market launch

• July 2011 – New Managing Director appointed

• July 2011 – Asian market launch

• August 2011 – in discussions with major Australian retail chain

• September 2011 – Major wholesale chain Metcash agrees to carry the full

EcoQuest range

• September 2011 – The National Childbirth Trust in the UK has agreed to stock

and sell the Little Takas products on its website.

Latest News & Announcements• 18.5.11 EcoQuest enters UK market with Little Takas

• 23.5.11 Australian e-tailer to sell Little Takas

• 27.6.11 Little Takas to be showcased in maternity packs

• 20.7.11 EcoQuest appoints global chief executive

• 29.7.11 EcoQuest launches Asian market entry in Hong Kong

• 29.8.11 Metcash & The National Childbirth Trust to offer Little Takas

Board & Management:

Sylvia Tulloch - ChairmanMscRespected scientist and entrepreneur with over 25 years experience in the establishment and management of high tech businesses.

Keith Herbert - Global Managing DirectorHighly respected FMCG executive previously in charge of PZ Cussons commercial operations across Europe, the Americas, Asia and Australasia.

Matthew Hicox - General Manager & Sales Marketing Manager, AustralasiaOver 18 years in sales and marketing, particularly in the FMCG & Pharmaceutical sectors.

Michael Greenup - Director of Operations & Procurement 35 years experience of owning and operating successful businesses, including 12 years consulting and sourcing in China and Malaysia.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for EcoQuest (ASX: ECQ).

CLEAN TECH

24

Executive SummaryKFSU Limited is a food ingredient company creating natural products from agriculture. KFSU’s

core competency is extracting fibre and concentrates from sugarcane, fruit and vegetables

for sale as ingredients to the global food industry. All products are natural, allergen free and

avoid the requirement for “E” numbers. KFSU is now actively supplying Japanese and Australian

customers and has entered it’s growth phase. The reason equity funding is required is for

increased capacity and growth, and to satisfy existing customer demand for our products in

Japan and Australia. Further production capacity will be funded out of retained earnings or

debt.

Competitive AdvantagesKFSU’s range includes individual products like Kfibre® which have very significant advantages

over competitors:

• Low Production costs

• Stable input costs

• Natural labelling - all jurisdictions

• Allergen free, chemical free processing

• No requirement for customers to use ‘E’ numbers on the ingredient panel

• Can be used with a wide range of food products without altering mouth feel or flavour

• Provides yield increases for baking and smallgoods customers (Kfibre® absorbs and retains

more moisture than any other natural product in this price range enabling customers to

reduce other input usage and costs )

• KFSU can track and trace products from farm to grocery shelf

• Simple to use by food manufacturers

Key Investment Highlights• High customer demand and recently confirmed 2011/12 sales forecasts

• Commercial sales have commenced in Japan and Australia

• Distributors have been appointed in Australia, New Zealand and Japan

• Customers in Japan, Australia, New Zealand and the UK have successfully used the product

• KFSU has pre-sold product into snack foods, small goods, chocolate and meat products

• KFSU will be trading profitably in 2011

• The IP has been registered and verified

• KFSU has a long term cane supply agreement with the Burdekin cane growers

• KFSU management are experienced at managing and growing small businesses

• R&D has shown further products are available for future launches and growth

Board & Management:

Gordon Edwards – Managing Director EngineeringBuilt, run and exited several SME’s.

Rod Lewis – Commercial DirectorBSc, Dip ManCorporate exec with high SME experience.

Hajime Masaki – Asian Sales DirectorSales qual/JapanUN Experience Japan / Tibet / Asia.

Janine Edwards – Company SecretaryManaged teams and 2IC Positions in SME’s.

Corporate StructureKFSU is a public unlisted company, with four direc-tors and an extensive international Advisory Board. All shareholders are issued with ordinary shares.

Exit StrategyKFSU is shaped for exit to competitors in three years. Key benefits to a buyer are the sugarcane fibre itself that others have tried but failed to emulate and the long term relationship base in Japan

Further InformationTo learn more about this opportunity, go to www.wholesaleinvestor.com.au and search for KFSU.

KFSU Ltd

Natural Food Ingredients

2006

Growth

Queensland, Australia

Growth Funding

Company Name

Sector

Year Established

Business Stage

Location

Seeking

NATURAL FOOD INGREDIENTS

25

RENEWABLE ENERGY

Executive SummarySun Connect Pty Ltd is a privately owned Australian importer and installer of solar power

components. Started in 2008 the company has over 70 employees and turnover north of $20

million for the current FY, double digit growth expected in 2012. Sun Connect has no debt and

strong operating financials. Offices in Perth, Sydney and Melbourne, a national installation

footprint, full Clean Energy Council membership and in the final stage of applying for ISO9001

Quality Accreditation. In June 2011 Sun Connect was a winner of the 2011 WA Business News

‘Rising Star’ Award - out of 400 entrants. Sun Connect is raising capital for the first time to fund

capital purchases and to expand ‘above the line’ advertising / marketing for further growth.

Competitive Advantages• Leading Australian solar provider in the niche premium space

• Able to boast the ‘5 Hallmarks of premium solar: ‘Highest Warranties, Output, Upgrade

Capacity, Quality, Levels of Service’

• Sales model contrary to the majority of ‘cheap’ market –– relationship-based selling/ support

rather than single-transaction based

• Average solar power system sale is 3.1kW and over $20,000 value – industry average is

1.7kW – reflecting premium space / nature of customer spread

• Completely unique direct sales and marketing models, including established marketing

assets

• First solar company in Australia to pioneer the ‘5 Year Customer Service’ SLA

• New trademark applications for protected marketing strategies

Key Investment Highlights• Past ‘start-up’ phase and in a sustainable and accelerating rapid-growth stage

• Contracted debtor sheet valued between $9M - $10M, with even spread to securitize capital

raising against

• No debt, strong financials and has operated at a healthy profit since its first year of trading

• Capital requirements will also be underwritten by large-scale state legislated solar subsidies

• 2 new business units are in the development stage - Energy Audits and Commercial Solar -

both expected to be government subsidized and booming new veticals

• Strong, well established brand and experienced management team to expand this brand

• Assets including patent pending IP starting to provide real returns, expanding into domestic

and international territories in a risk-averse, staged fashion

Sun Connect Pty Ltd

Renewable Energy

2008

Growth

Perth, Sydney & Melbourne, Australia

Company Name

Sector

Year Established

Business Stage

Location

Board & Management:

Mark Tuke - CEO BComFormer CEO of public software company, exit to Thomson Reuters. 16 years in business development - IT/tech enterprises in Australia & UK.

Gordon Impey - GMBCom, Hons BCom, MBATelkom (South Africa) / Eskom (national power provider, SA) as well as Australian management postings at Amcom, PerthIX, Elders.

Alistair Gibson - Strategic ManagerBachelor of Laws, Master of Technology ManagementFormerly Country Manager for Gurango Software, MD of Absalom Australia, corporate strategy consultant at PricewaterhouseCoopers.

Corporate StructureSole director, flat management structure, ownership structure is 3 shareholders, CEO (60%), Ops Manager (20%), Technical Manager (20%).

Exit StrategyExpand national footprint and growth in UK market - acquisition by integrated offshore cleantech manufacturer / distributor, or IPO.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Sun Connect.

26

CONSUMER GOODS

Executive Summary• EHNZ is a wholesaler/distributor of NZ milk powder products in the North Asia region

• Premium NZ milk powder products are in high demand in mainland China (in particular) and

other developed Asian nations

• EHNZ has signed a long term distribution agreement for Mi-NZ, a new NZ made premium

infant milk formula

• Strategic distribution alliance being finalised (letter of intent received) with a highly reputable

Chinese government owned trading company (SOE)

• Expressions of interest have been received from other mainland Chinese customers

• Lease terms agreed for a retail property and sales office located in a duty-free trading zone

on the border between HK and China to support own sales of Mi-NZ

Competitive Advantages• Low cost importer and distributor in key Asian markets

• Exclusive distribution rights for Mi-NZ IMF product range in Hong Kong, Macau, and 19

Chinese provinces; plus first right of refusal over Japan, South Korea, Taiwan and Singapore

• Strategic distribution alliance with a Chinese SOE

• IMF entry barrier overcome due to access to dairy product import license through Chinese SOE

• Retail shop and sales office in a duty-free trading zone on the border between Hong Kong

and China to support own sales of Mi-NZ

• Other strategic alliances with distribution and retail partners in mainland China

• Import duty removal from 2012 under FTA between NZ and China

Key Investment Highlights• Infant milk formula (IMF) is projected to be the fastest growing food and beverage segment in

China over the next five years

• NZ sourced premium IMF is viewed by customers as a proxy for quality

• EHNZ has secured exclusive distribution rights for Mi-NZ IMF product range in key markets

• Strategic alliance being finalised with a Chinese SOE to facilitate China Import and Quarantine

licensing, importation and sub-distribution in Southern China

• Negotiating further alliances in respect of other wholesale/retail distribution channels in

China to ensure that customers receive genuine quality premium NZ milk powder products

• Retail shop and sales office presence in Shenzhen, China, duty-free zone

• Immediate market opportunities in Hong Kong and China due to recent local IMF scandals

and contamination concerns over Japanese imported products

• Access to additional premium IMF brands to support alternative distribution channels

Eastern Harmony New Zealand Limited

Food and beverage

2011

Commercial – Phase 1

Australia, New Zealand, Hong Kong, China

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Edward Stauber - CEOPreviously Vice President of Asia Pacific, Novartis Vaccines & Diagnostics

Randolph van der Burgh - CFOPreviously Partner, Ernst & Young

Michael Lees - COOPreviously Director Structured Asset Finance, HSBC Hong Kong

Linda Cheung - COO, HK & PRCSelf-employed marketing consultant for the past 15 years

Corporate StructureEHNZ is a New Zealand registered private company (CN 1550480)

Exit Strategy• The short to medium-term strategy is to grow the business naturally and/or by acquisition• Should the right opportunity arise, EHNZ would consider a sale to a strategic investor or IPO

Further InformationTo learn more about this opportunity, go to www.wholesaleinvestor.com.au and search for Eastern Harmony.

27

TECHNOLOGY

Board & Management:

Brett Schwarz - Managing Director and CEO Co-founder and instrumental in building the company since inception. 20 years experience in accounting and consulting.

Iain Kirkwood - Non-Executive ChairmanOver 35 years experience with listed and healthcare companies.

Dr Jason Chaffey - Chief Technical Officer Actively involved in MEMS technology for over 10 years. Extensive experience in government research and university research laboratories.

Joe Baini - Non-Executive DirectorOver 20 years experience in the pharmaceutical industry, focused on commercialisation, marketing and sales.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Bluechiip Ltd (ASX:BCT).

Bluechiip Ltd (ASX:BCT)

Technology

2003

Early Commercialisation Phase

Victoria

IPO Offering

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive SummaryBluechiip has developed a groundbreaking asset tracking solution based around a chip which

offers unique features over traditional tracking methods of labels (hand-written and

pre-printed), barcodes (linear and 2D) and Radio Frequency Identification (RFID).

Bluechiip is a totally integrated tracking and management solution from identification, tracking,

retrieving, bio storage and monitoring, offering process assurance and operational certainty in

low temperature environments.

The inherent MEMS or microtechnology platform of the bluechiip technology allows the unique

identification of tagged items and tracking of critical factors, such as temperature, to provide

quality, assurance and custodianship.

Initial applications for the bluechiip technology are in the high-growth biobanking sector.

Current Projects• Secure adequate funding to ensure product and business development programs are

fully funded over the next 2 years

• Complete product development to point of having commercially saleable products

• Tooling up for high volume commercial production with manufacturing partners and OEM’s

• Perform industry pilot trials to continue to validate technology, from which white papers/

business cases as well as scientific papers can be prepared and endorsements provided

• Perform global business development activities to secure the initial target market of

biobanking, including securing distributors and channel partners

• Secure endorsement from end-users and Key-Opinion-Leaders (KOL’s)

• Ongoing protection and expansion of current IP

Key Investment Highlights• Validated large markets with immediate application in biobanking (one of fastest growing

areas in healthcare), with future applications in other healthcare areas, security/defence,

cold-chain logistics/supply chain, industrial and manufacturing

• Validated technology under extreme conditions and conducted successful pilot trials at

eminent Australian medical institutions including Peter Mac

• Ready for commercialisation - poised for volume production with global manufacturing

partners including STMicroelectronics

• Secured Ziath as first distributor and in active discussion with other major potential partners

• Secured valuable IP portfolio including granted patents, all wholly owned by company

• Management and Board of Directors have relevant experience to take company

into commercialisation

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:BCT

7,987,713

$0.1500

0.2500

0.1400

Share Information As at 6 September 2011

ASX:BCT 6 month price chart 0.22

0.20

0.18

0.16

0.14

0.12

0.08

0.04

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

28

TECHNOLOGY/FINANCIAL SERVICES

Executive SummaryEquiome is a specialist financier of all aspects of large corporate software projects, which

allows companies to realise immediate commercial benefits from the usage of the solution,

without the risk of project failure or the requirement for any capital investments. This, aligned

with Equiome’s rapid deployment methodology and partnering approach, creates a totally

unique customer value proposition that addresses the three biggest challenges facing

customers commencing large software projects; initial funding, alignment of costs to benefits

as well as project execution capabilities. This solution has major benefits for a wide range of

large corporations, both in Australia and Internationally.

Competitive Advantages• Equiome’s model is a totally unique and new way of resolving a business problem common to

large software project in most major corporations

• The solution is designed to easily scale, providing multiple streams of business benefits for

each customer

• Equiome is technology and vendor independent, giving customers more control

• Equiome funds all aspects of the software project

• Equiome charges a single monthly fee for all aspects of the solution

• It is one of the few approaches that look at the problem from a business benefit/output,

rather than a series on inputs

• Have developed a rapid deployment methodology, with a heavy focus on the realisation of

quantifiable business benefits

Key Investment Highlights• Highly experienced leadership team who clearly understand the market and the intrinsic

value of software projects

• Equiome is creating a new investment asset class, by transforming the current intangible

software assets, into tradeable commodities

• The model is based around initial and annuity revenue streams

• Equiome is in active discussions with a number of major Australian organisations for this

solution

• The model is based around the re-usability of solutions; small, incremental changes can

create significant value

• Equiome has invested significant time to create and develop relationships with major

companies to deliver this solution

• This model is absolutely unique, and has a substantial domestic and International market

Board & Management:

Steve Hanna - Managing Director A background of 25 years in IT, working for large technology vendors, holding key roles in software sales and vendor finance

Corporate StructureEquiome Pty Ltd is a privately held Australian company.

Exit Strategy: Equiome is aiming for revenue and asset growth, followed by a strategic trade sale in 3 – 5 years.

Equiome

Technology / Ecommerce / Finance

2007

Early Commercialisation Stage

New South Wales

Capital Raising

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Equiome.

29

INTERNET/IT

Executive SummaryCollective Intelligence Group (CIG) specialises in wireless monitoring and reporting solutions

for mobile and remote assets. CIG solutions deliver operational and financial efficiencies to

partners and their customers. CIG is ‘the missing link’ in efficient asset management.

CIG has over 10 years proven capability with over 50% market share in its key market. CIG

technology is transformative enhancing the offerings of key partners such as Toyota, Nissan

and Linde Materials Handling, and of end-users including BHP Billiton, DHL and Fuji Xerox.

CIG is seeking new partnerships in sectors that it operates in - Industrial, Fleet, Utilities and

Inventory. Partners are industry participants seeking to improve performance, productivity &

compliance.

Competitive Advantages• Market Presence: Over 50% market share achieved in Australian forklift sector and ability to

leverage presence into new opportunities. CIG has established deep OEM, distributor and

end-user relationships

• World Class Technology: CIG is a transformative technology with its monitoring and reporting

capabilities. In tender scenarios, CIG products are often the only fully compliant option

• Compelling Benefits: Intelligent solutions save 90% of time-to-invoice, improve business

efficiency by 20%, reduce asset costs by 25% and reduce compliance costs by 50%

benefiting entire supply chain including the leasing company, the distributor, operators and

end-users

• Brand Recognition: Market visibility and name recognition for CIG

Investment Highlights• High Market Penetration: Existing key partners include Toyota, Nissan and Linde Materials

Handling

• Millions Invested: Product and business systems as well as fulfilment infrastructure in place.

Operations established in UK to serve Europe & US

• Strategic Value Creates Unique Market Footprint: Cost and operational efficiencies gained for

end users demonstrates strategic value for manufacturers, owners, and operators

• Expansive Market Potential: With multiple features meeting multiple needs across multiple

markets, CIG has successfully proven itself in the Industrial, Fleet, Utilities and Inventory

markets

• Partner Focused: Groups utilising CIG have a partner that is creative, responsive, forward

thinking, flexible and reliable in creating integrated, unique, intelligent solutions

Collective Intelligence Group P/L

Technology

2001

Expansion

Sydney, NSW

Commercial Partnerships

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

James Hayes – Managing Director25 years in leading IT businesses. Built a world-class reputation with companies inc. Toyota, Linde, NSW Rail Authority and NSW Water Board.

Gary Squire – Director15 years in sales and senior management primarily in materials handling, dealing with top 100 companies. In UK for CIG targeting US & Europe.

Robert Hazell – Board Advisor40 years as Director of a Tier 2 construction company. An award winning leader within the Family Business Association of Australia.

Brad Klaffer – DirectorFinancial management expert with 10 years in IT & 15 years in CFO positions. Most notably with Hazell Bros when they made the BRW Fast50.

Corporate StructureCollective Intelligence Group P/L is the parent company with R&D and IP licensing responsibilities. There are 7 operational subsidiaries.

Exit Strategy: The priority is to capitalise on its current market leadership by expanding into new markets by product and by territory. Leadership in multiple markets makes CIG an attractive trade sale target.

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Collective Intelligence Group.

30

Mint Wireless Limited (ASX:MNW)

Telecommunications/ IT

Early

Sydney, Singapore, Kuala Lumpur,

London

Company Name

Sector

Business Stage

Location

Executive SummaryMint Wireless Limited (Mint) is a global payments and mobile transactions company listed on

the Australian Securities Exchange (ASX: MNW). Mint’s core business specifically focuses on

the developed and emerging markets.

Our vision is “To become the largest, global micro-transactions processing company for the

poorly banked and cash economy”

Mint’s subsidiary, Intermoni is unique from other mobile money solutions that are evolving

globally:

• ‘Bricks and mortar’ deployment and front end, bridging market gaps between the developed

online world and the poorly banked, cash economy

• Scalable: self-service ‘plug-and-play’ cash acceptance kiosks – simple to operate with ability

for rapid deployment

• Focus on micro valued transactions below USD$20

Current Projects• Malaysia – First developing country deployment and roll out of micro-transaction terminals.

Malaysia is the 2nd largest remittance-sender country amongst developing countries with

~2.4 million migrants remitting $6.8 billion annually. Binding order received from distributors

in July 2011 for 3,000 terminals in Malaysia over the next 6 months (valued at ~ USD$5M).

• Opening new markets in Asia (discussions underway in Indonesia, Singapore, Hong Kong and

Vietnam markets) with further opportunity to scale globally.

• Advanced discussions with leading microfinance cooperatives in one of the most vibrant

microfinance countries in the world for the use of Intermoni’s micro-transaction terminals for

the repayment of micro-loans.

Key Milestones & Investment Highlights• Successful launch of Intermoni (fully owned subsidiary of MNW) in Singapore, focused on

deploying micro-transaction services to the poorly banked population of emerging markets

globally

• Acquisition of 51% of J&C Pacific in Malaysia, immediately providing the Company with

operations and revenues in Malaysia and mobile technology and infrastructure that the

Company will use as a base to develop its suite of micro-transactions services

• Excellent progress with terminal rollout: Orders received for 3,000 terminal in Malaysia over

the next 6 months and advanced discussions with key partners in other South East Asian

markets

• Capital raising: Balance sheet strengthened with over $2 million raised via institutional

placement and share purchase plan

Board & Management:

Terry Cuthbertson - Non-Executive Chairman B.Business, ACAChairman of seven ASX listed companies. Wide corporate finance experience (including merger and public offerings) as well as with the IT industry.

Alex Teoh - CEO & Managing DirectorB. Science (Information Systems / Finance)Extensive experience in Australasia with global management consulting practices specialising in the IT & Telco sector.

Dr. Seng Chuan Tan - Non-Executive Director Mechanical engineering, Masters and Ph.D in Engineering and ScienceExecutive Director of Malaysian KLSE listed Insas Berhad. Wide experience in the IT and payments industry.

Andrew Teoh - Executive DirectorBachelor of Commerce (Accounting/ Finance)Extensive experience with emerging consumer and telecommunication technologies with prior experience in the pre-paid Telco industry.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Wireless Limited (ASX: MNW).

INTERNET/IT

Share Information

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:MNW

20,673,181

$0.0830

0.1500

0.0200

As at 6 September 2011

ASX:MNW 6 month price chart

0.10

0.05

0.00

-0.05

3

2

1

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

31

TECHNOLOGY

Board & Management:

International BoardSteve Millard (Founder) AU Former Head EPIC Records AustraliaRupert Perry (Chairman) US Former Head EMI Music US|Euro|UKBob Jamieson US Former Chairman RCARichard Rowe Former Global President Sony/ATV PublishingJim Caparro US Founder Def Jam Music/CEO Polygram/Island Def Jam Ryan Dudley US Global Tax Lawyer NYDavid Simpson AU Fmr Snr Managing Partner, Freshfields SingaporeChris Moss AU Former MD Warner Music Australia

Advisory BoardDr Tom McKaskill AU Author | Entrepreneur | StrategistChris Adams US Media Pioneer | Film Industry ExecutiveTim Eldridge US Ad Agency | Brand + Communication Strategist

Corporate StructureBecause Group International is an Unlisted Public Company.

Exit StrategyIt is the intention of the Board to list on a suitable exchange at an appropriate time. A number of vertical markets have been identified where Skyhub could provide a high value capability.

Further Information:To learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Because Group International.

Because Group International Ltd

Global Media

2005

Expansion, Pre-IPO

Sydney, Australia

Pre-IPO Funding

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Executive SummaryBecause Group International Ltd (Because Group) is a global digital media distribution company

with operations in the US, the UK and Australia. Because Group has developed a unique global

distribution infrastructure for media content online.

Because Group is the parent company of the Skyhub Digital group of companies, Echospin™

(NY) and has contracted to purchase Push Entertainment™ (UK). The combination of online business

technologies controlled by Because Group is branded as the digital future solution (dfs™).

Competitive Advantages• Internationally recognized Management Team with strong links in the Media +

Entertainment Industry

• Global Technical Team with experience in online business API’s and payment technologies

• Mature proven platform and payment gateway that is versatile to the needs of M&E owners

and provides a fast-track solution for any M&E owner, aggregator and retailer to participate in

paid digital distribution

• Enables movie rental brands (Movie Retailers) to sell direct to consumers

• Enables content streaming brands (Internet Service Providers, Telco’s) to sell direct to

consumers

• Offers better cash flow & faster payments to content owners – 5 months down to 72 hours

• Currently doing business in the US, Canada, UK and Australia with Universal, EMI, Warner

Key Investment Highlights• $5.5 million raised to date.

• Because Group USA established September 2010

• Sony Music Approved Global License & acquisition Bandit.FM digital platform

• Skyhub Digital stage 1 complete

• Global Payment Gateway - Stage 1 complete

• Global Bank Network - Stage 1 complete

• Trading enabled to 54 countries

• International Board assembled

• Acquisition of Echospin October 2010

• Push UK Acquisition - Term sheet signed Nov 2010 - (www.pushentertainment.com)

• EMI Global distribution agreement signed

• Universal USA distribution agreement signed

• EPIC records (Sony Music USA) utilising platform

• Granted patents for digital media distribution

32

Web Solutions Your Online Success

TECHNOLOGY/FINANCIAL SERVICES

Executive SummaryExa is Australia’s largest Online / Apps / Web / Mobile company, with over 1000 clients.

Exa generates significant recurring revenue from its client base and is ranked at the top of

Google for online marketing, tools and technologies.

Exa operates 24x7, 365 days per year, is the most efficient player in its space and has unique

ecommerce solutions for a range of social media and smart phone technologies.

The business maintains high margins due to over $10M+ invested in back end & support

systems.

Exa is well positioned to capitalise on the rapid growth in the digital economy and is seeking to

raise up to $2M for product and geographic expansion.

Competitive Advantages• Senior Management are equity holders

• Leading edge technology (Online / Apps / Mobile)

• Cost Efficient

• National Footprint

• Brand

• Broad client base

• Explosive growth in mobile apps

• Genuine 24x7x365 operations

Key Investment Highlights• Experience Board & Management Team

• International Market Potential

• Blue Chip Client Base (top tier banks)

• Multiple revenue streams

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Exa Web Solutions.

Exa Web Solutions

Internet, Technology

2000

Expanding

Melbourne, Australia

$2 million

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Peter Ball - Managing Director M.D.25 years of building successful technology companies.

Mitch How - CFOLawyer and CPA4 years at EXA. Similar previous roles in Media, Music & Tourism in Australia, UK & Europe.

Jim Vincent - Special Operations Manager B.Sc, Maths, Physics & Comp 30 Years @ IBM. Programs in 22 languages, 6 patents and extensive patent work.

Corporate StructurePrivate Company Limited by shares.

Exit Strategy: Exa aims to list on a suitable exchange at an appropriate time.

33

TECHNOLOGY

Executive SummaryQanda Technology owns 2 operating businesses.

Marketboomer provided online procurement services and technology to hotels in 11 countries.

Customers such as Intercontinental, Starwood, Mirvac and Hyatt hotels save money through

better pricing and process improvement. They also maintain robust workflow and auditability. It

generates revenues through annual recurring license fees charged to buying hotels as well as

turnover-based fees charged to suppliers.

Webspy sells it’s Vantage software globally that allows companies to report on network

Internet usage across all staff and networks. This enables them to better optimise network

bandwidth, speed and costs. It also allows forensic analysis of network traffic. Compliance,

Duty of Care and Security are all improved with its reporting suite.

Current Projects• Launch Marketboomer in the USA via existing customers such as Starwood Hotels and

Resorts

• About to release multilingual capability in Marketboomer to drive South East Asia sales

• Implement excellent mobile reporting dashboards for customers executive level users

• Increase Webspy sales in USA via combined direct and channel sales efforts

• Launch of new streamlined global pricing and simplified product range for Webspy

• Restructuring company entities to eliminate unnecessary costs and administration and tax

• Consolidating reporting and internal systems to drive corporate efficiency

Key Miles Stones & Investment Highlights• Recently restructured to reduce annualised costs by over $2.4m

• US market potential 20 times Australian run rate. Ready to implement US growth strategy.

• Webspy generating 1.4m in sales with only 5 staff and ready to grow

• Technology platform update nearing completion to increase web based sales chennel

Board & Management:

Nathan Gyaneshwar - CEO & Executive DirectorNathan founded Marketboomer in 1997 and has extensive mgt, cost control and procurement experience.

Ben Donovan - Non-Executive DirectorBen holds a B.Commerce in Finance and Commercial Law. He is a Chartered Secretary with ASX experience.

Kim Redstall - Non-Executive Director Kim has significant operational, sales, marketing, and M&A experience in the technology sector.

Declan Monahan - Non-Executive Director Declan has over 20 years experience in senior mgt roles in the hospitality, education and IT sectors.

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for Qanda Technology.

Qanda Technology Ltd (ASX:QNA)

Technology

2000

Sydney

Company Name

Sector

Year Established

Location

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:QNA

3,093,532

$0.0050

0.0180

0.0040

Share Information As at 6 September 2011

ASX:QNA 6 month price chart

0.04

0.03

0.30.4

0.20.1

0.03

0.02

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

34

Executive SummaryIntellect Projects is a property development company specialising in residential apartment

and retail developments within the inner suburbs of Melbourne. We have 25 year track

record of successful property development and have forged a reputation for quality projects

underpinned by an intimate knowledge of our target market and long-standing industry

relationships.

Intellect is entering an exciting next growth phase and is seeking co-investment to launch

our current project, a boutique apartment complex located within 10kms of the city centre.

Intellect seeks to strongly align its interests with those of investors and to this end, is offering

an attractive profit share return structure on this development.

Competitive Advantages• 25 yrs+ experience in property development within the inner city suburbs of Melbourne.

• Off market development opportunity.

• Wholesale purchase rates.

• Management undertaken by an experienced board and consultants.

• Partnering with an experienced developer and other investors increases your ROI and de

creases risk.

Key Investment Highlights• The Fund will be managed on a performance basis meaning that investors will receive a

return on their capital before any performance fee can be awarded to the Manager. After the

initial hurdle return has been distributed, the Unit Holders will then be given an additional

share of the Final Net Proceeds (Net Profit) of the Fund through their holding of Ordinary

Units.

• Our current project and investment opportunity has progressed to a point where it is signifi

cantly derisked and awaits the addition of capital to execute.

• Proven market demand for finished product (quality $450K-$850K residential apartments

close to CBD)

• Majority of the apartments are pre-sold prior to construction, allowing a more accurate return

and a settlement of the pre-sold apartments soon after completion of construction.

• This project offers the opportunity to form a relationship with a quality developer and to

invest in future projects.

Intellect Projects Pty Ltd

Property Development

2004

Ongoing

Inner Melbourne

Strategic Investors & Fund Managers

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Peter Motalli - Managing Director Registered Commercial & Residential BuilderHas over 25 years experience in the building industry and has been developing inner city projects through the last 16 years.

Stan Zaslavsky - Marketing AdvisorLicensed Estate AgentHas over 10 years of marketing development property experience.

Corporate StructureThe investment fund is structured as a unit trust and is an unregistered managed investment scheme under the provisions of the Corporations Act 2001.

Exit StrategyOnce all the apartments in the development are sold and all profits after costs and fees are realised, investors can withdraw their equity and any capital gain. Target project completion is 18-24 months.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Intellect Projects.

PROPERTY

35

PROPERTY

Executive SummaryBlackWall SPORTSMED Property Trust is a fixed term property investment trust that has

contracted to acquire the SPORTSMED Hospital and adjacent SPORTSMED Clinic in South

Australia, a leading orthopaedic and sports injury practice with over 130,000 patients per year.

The Trust is forecast to generate tax effective distributions starting at 9% per annum paid

quarterly. Investments are not diluted by acquisition costs and an initial investment of $1.00

per Unit will be backed by 100 cents of NTA. Rental income is forecast to grow by at least 3% per

annum. BlackWall is a real estate investment linked to the fast growing and non-discretionary

healthcare industry.

Competitive Advantages• Strong lease covenant to a highly regarded operator on a triple net lease with 20 year term.

SPORTSMED was rated as the No.1 private hospital in a recent Medibank survey.

• Alignment of interest. SPORTSMED has first rights of refusal to purchase the asset as a co-

owner and will retain 25% ownership.

• BlackWall is a vertically integrated property funds management business. Its directors and

senior managers have structured and managed direct property investment since the early

1990’s. Trusts structured by Blackwall of a similar type have paid all distributions through the

GFC and shown strong capital growth.

• As a special offer to Wholesale Investor subscribers BlackWall will rebate brokerage of 2% to

each investor investing through the special Wholesale Investor webpage. With this offer the

total cash return in the first year will increase to 11%.

Key Investment Highlights• Strong cash yield of 9% pa paid quarterly with tax benefits.

• The Trust is structured to minimise transaction costs and, as such, investors’ initial NTA is

100 cent per $1 invested thus enhancing capital returns.

• The trust has been given a AA- rating by Property Investment Research (PIR) which indicates

that PIR believes it is an above-average grade product, exceeds the minimum requirements

of its review in a number of key evaluation parameters and has an above-average risk/return

trade-off.

• The Trust should be able to consistently generate above-average risk adjusted returns.

Board & Management:

Stuart Brown - Chief Executive Officer and DirectorMore than 15 years experience in property investment. Involved in debt and equity raisings on listed and unlisted property valued at more $500 million. Formerly with leading law firms Mallesons and Gilbert & Tobin.

Richard Hill - Independent Chairman and Non-Executive DirectorExtensive investment banking experience in the US and Hong Kong. Founding partner of corporate advisory firm Hill Young & Associates. Chairman of the Westmead Millenium Institute for Medical Research.

Joseph (Seph) Glew - Non-Executive Director Over 20 years experience in the commercial property industry in NZ, Australia and the US. Non Executive director with a number of listed companies in NZ and Australia.

Robin Tedder - Non-Executive Director Over 30 years experience in investment and financial markets. Chairman of Vintage Capital and a former member of the ASX.

Corporate StructureSingle asset special purpose trust registered as a Managed Investment Scheme under the Corporations Act 2001.

Exit StrategyAsset sale on expiry of the 7 year term.

Further InformationTo learn more about this opportunity go to www.wholesaleinvestor.com.au and search for BlackWall.

BlackWall SPORTSMED Property Trust

Real Estate/Medical

2011

Adelaide , South Australia

$10.6 million

Company Name

Sector

Year Established

Location

Seeking

36

Executive SummaryTRAC Financial Group Ltd (TRAC) is an Australian domiciled specialist portfolio and fund

management firm. Utilising exceptional prior performance, the TRAC Absolute Return Fund

was launched oversubscribed in November 2009. Since inception until 31 May 2011, this fund

returned to investors 102.54%.

TRAC is now pleased to announce the launch of the TRAC Absolute Return Fund – Issue 2,

providing investment exposure to the manager’s successful trading strategies.

Competitive Advantages

Key Investment Highlights• Alternative asset exposure, diversifying against traditional investment strategies.

• Aims to provide investors with consistently high returns irrespective of global market

conditions, with moderate levels of risk.

• Targets a return above the global asset class with the strongest performance.

• Aims to achieve this target by successfully employing discretionary; systematic; arbitrage;

and event driven trading strategies, while continually remaining market neutral.

• Trades across asset classes and over a wide but familiar spectrum of markets around the

globe.

• Will not be limited to the adherence of any specific investment philosophy, but rather

focus on the most effective method of generating profits within the parameters of its risk

management system.

FUND MANAGEMENT

Board & Management:

Thomas Coughlin - Chief Investment Officer 10 + years experience in the Investment and Fund Management industry. Sits on the board of four public investment and commodity public companies.

Michael Coughlin - Company Secretary 37 years experience in the Accountancy and Financial Services industries. 33 years as principal.

William Ralston - Non Executive DirectorProminent Queensland businessman and property developer for 35 + years.

David A Charles – DirectorLLB (commercial); GD Legal PracticeActed for some of the world’s largest and most prominent entities across four continents. An experienced director and a dynamic business oriented lawyer, with a focus on corporate governance.

Corporate StructureTRAC Absolute Return Fund – Issue 2 is a Unit Trust with TRAC ARF 2 Pty Ltd as Trustee. TRAC Financial Group Ltd is the manager.

Exit StrategyMonthly redemptions are available to all investors.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for TRAC Financial.

TRAC Financial Group Ltd

Fund Management

2009

Expansion

Brisbane

Investment Funds

Company Name

Sector

Year Established

Business Stage

Location

Seeking

37

PROPERTY

Executive SummaryFolkestone is a real estate investment, development and funds management company listed

on the ASX (Code: FLK).

Following an Extraordinary General Meeting of Shareholders in March 2011, the New Board and

senior management have recapitalised the Company by successfully raising $31.5m and are

now implementing a new strategy to enable Folkestone to take advantage of the attractive

opportunities created by the dislocation in real estate and financial markets across:

• investment types: direct investment, joint ventures and co-investing in Folkestone managed

funds;

• capital structures – ordinary equity, preferred equity and mezzanine debt; and

• sectors – office, retail, industrial, residential and social infrastructure.

Folkestone’s on balance sheet activities will focus on value-add and opportunistic investments

while Folkestone’s funds management platform (Equity Real Estate Funds Managament) will

offer real estate funds to private clients, high net worth individuals and select institutional

investors across core, value-add and opportunistic real estate investments.

The focus of Folkestone’s investment strategy will be on delivering capital growth for

Shareholders. Folkestone will target an after-tax return on equity of 15% per annum on a rolling

three year basis.

Current Projects• Clifton Hill – Melbourne (residential apartments)

• Altona North – Melbourne (bulky goods/industrial)

• Mickleham – Melbourne (industrial land)

• Karratha - WA (residential accommodation)

• Officer – Melbourne (residential land sub-division)

• Tivoli Development Fund (residential development fund)

Key Investment Highlights• New experienced board and management team

• Alignment of interest – senior management own more than 12% of the Company

• Unique offering in the listed real estate sector

• Positioned to capitalise on attractive real estate opportunities

• Exposure to funds management platform – Equity Real Estate Funds Management

• Strong investment sourcing capabilities

Company Name

Sector

Year Established

Business Stage

Location

Board & Management:

Garry Sladden - Non-executive Chairman Garry is a business and strategic adviser who has a diversified business background in the areas of real estate, private equity, banking and finance.

Greg Paramor - Managing DirectorGreg has been involved in the real estate and funds management industry for more than 40 years. Greg was the CEO of Mirvac between 2004 and 2008.

Ben Dodwell - Head of PropertyBen has been responsible for the development of retail centres, integrated mixed use and apartment projects at Lend Lease and Stockland.

Adrian Harrington - Head of Funds ManagementAdrian is the former CEO of Funds Management, US and UK at Mirvac and has more than 18 year experience in funds management and real estate industries.

Jonathan Sweeney - Chief Operating OfficerJonathan has more than 24 years experience in the finance services industry and was the former Managing Director of the Trust Company from 2000 to 2008.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Folkestone (ASX: FLK).

Folkestone

(ASX:FLK)

Property

1960 – listed on ASX June 2000

ASX Listed

Australia

Code

Market Capitalisation

Current Share Price

52 Week High

52 Week Low

ASX:FLK

33,375,251

$0.0900

0.1500

0.0850

Share Information As at 6 September 2011

ASX:FLK 6 month price chart

0.12

0.10

0.08

0.06

1.2

0.8

0.4

Apr 2011 May 2011 Jun 2011 Jul 2011 Aug 2011 Sep 2011

38

Executive SummaryThe Company operates in the franchise industry and offers three (3) key services:

• Licensees –– Bizpanel owned Franchises with a Licensee acting as the “Franchise Manager’

under agreed terms; and

• Franchisees –– Providing a below 80% Loan to Value ratio, loan for the purchase of an

approved Franchise License. The Franchisee under this arrangement holds the Franchise

License directly and the Company takes a fixed charge over the Franchise as security; and

• Business Support –– Essential services such as bookkeeping and accounting in addition to

desired services such as business planning, business coaching and sales training

The goal of Bizpanel is return based, therefore each of the 3 key services aims to deliver a

minimum return.

Competitive Advantages• Preferential agreements and terms with Franchisors;

• Exclusive funding agreements with franchisor;

• Highly skilled management team professionals;

• High scalability and no direct competition

• Business Support services tracks financial performance to the franchise;

• Bizpanel always retains the right to take-back the Franchise Business, appoint external

management, sell or dispose of the asset.

Key Investment Highlights• Franchise industry specific

• Below 80% loan to value ratio

• Investor places 100% of investment on term deposit for the term of the debenture

• Dual income stream from bank deposit rates and investment

• Foreign exchange options available for offshore investors

• Investors can nominate their preferred franchise

• Franchise sector anticipates double digit growth for 2012

• Investment return expected from 12% pa for funds held on term deposit as security or up to

17,5% pa for direct investment.

• Suitable for superannuation including self managed superannuation

FUND MANAGEMENT

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Bizpanel Limited.

Bizpanel Limited

Finance and Investment

2011

Operational and seeking investors

Sydney

$5m initial

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Matthew Holland - M. Director Financial Planner, RG 146 Diploma financial ServicesThe largest multi franchise owner for a major franchise. Matthew sold in 2011 yielding the largest multi million dollar trade sale for the franchise group.

Chris Kalpage - DirectorSolicitor Chris Kalpage a Solicitor with the Law Society of New South Wales for the past 27 years.

Andrew Garouniatis - DirectorAccountant CorporateAndrew has worked with Blue Chip organisations for the last 26 years. A member of the Institute of Public Accountants.

Anita Olsen - Director Accountant / CPAAnita Olsen started in her accounting practice in 1994 as a registered tax agent and accountant.

Corporate StructureAn unlisted Public company and financial services license number 404453. Daily management is undertaken by Directors Matthew Holland and Chris Kalpage.

Exit StrategyDebentures:Fixed Three (3) or five (5) year term;From 12% - 17.5% per annum;Paid Quarterly, bi annually or annually: May be redeemed early upon application to Bizpanel and the bank.

39

FUND MANAGEMENT

Executive SummaryBullion Capital Limited (BCL) is an Australian domiciled specialist bullion brokerage and fund

management firm. Capitalising on its unique position and strategic advantages within the

physical precious metals industry, BCL is pleased to offer a range of precious metal Bullion and

Ore funds exclusively to Sophisticated and Professional investors.

All funds have investment strategies implemented to provide a relative return over their

underlying spot bullion price, while providing the highest level of quality assurance and safety

in the industry.

Current FundsBCL is offering investment in the following physical precious metal funds:

• Gold Bullion

• Silver Bullion

• Platinum Bullion

• Gold Ore

• Silver Ore

• Platinum Ore

Key Investment HighlightsBullion Funds:

• The investment objective is to marginally outperform the underlying inter-bank bullion spot

price, while providing the safest, most flexible and cost effective allocated bullion

investment vehicle available globally.

• The funds have an exclusive market making agreement with Australian Bullion Exchange

(ABX).

• Real-time trading with 3 day settlement.

• Monthly physical delivery and vault inspection available.

• Currency hedging available.

Ore Funds:

• The investment objective is to significantly outperform the underlying inter-bank bullion spot

price, while providing a safe allocated bullion investment vehicle.

• Sources unrefined metal and sells to refiners at a profit.

• Supply agreement in place with Australian Bullion Refinery.

• Currency hedging available.

Company Name

Sector

Year Established

Business Stage

Location

Seeking

Board & Management:

Thomas Coughlin - Chief Investment Officer 10 + years experience in the Investment and Fund Management industry. Sits on the board of four public investment and commodity public companies.

Dylan Kelly - Technical ManagerBBus Com, GCME, M.ScMining financial evaluation specialist. International and cross cultural experience in a variety of commodities and operating environments.

Michael Coughlin - Company Secretary 37 years experience in the Accountancy and Financial Services industries. 33 years as principal.

William Ralston - Non Executive DirectorProminent Queensland businessman and property developer for 35 + years.

David A Charles – DirectorLLB (commercial); GD Legal PracticeActed for some of the world’s largest and most prominent entities across four continents. An experienced director and a dynamic business oriented lawyer, with a focus on corporate governance.

Corporate StructureThe Bullion Capital Funds are Unit Trusts with corporate Trustees. Bullion Capital Limited is the manager of the Funds.

Exit StrategyBullion Funds - Real-Time trade execution with 3 day settlement, plus monthly physical delivery available.Ore Funds - Monthly redemptions.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Bullion Capital Limited.

Bullion Capital Limited

Fund Management

2010

Expansion

Brisbane

Investment Funds

40

Executive SummarySince opening the initial public offer (IPO) for Flinders Exploration Limited (FEX) in October 2010

the phosphate and diamond asset base of the Company has been strengthened by continued

exploration. This has upgraded our existing Copper Claim prospect in SA to prefeasibility study

status. The Company has also gained the right to acquire two new gold projects; the Black Cat

gold development project near Coolgardie in WA and the Porters Mount gold exploration project

in the central Lachlan area of NSW.

Current Projects• Copper Claim is located in the southern Flinders Ranges, and has potential for an oxide body

of 10 to 20 million tonnes at a grade of 0.25% to 0.35% copper and contains an Inferred

Mineral Resource of 22 million tonnes at an average grade of 0.25% copper. On listing the

Company will commence a prefeasibility study into developing the project.

• Black Cat has the potential for near term development of a JORC-compliant gold resource

(317,000 tonnes at 2.1 g/t Au). FEX has carried out a scoping study from which gave a

positive result.

• Porters Mount is located in the major copper-gold province of central New South Wales and

has the potential for discovery of a large porphyry copper-gold body.

• FMS JV: FEX’s assets lie in the JV Agreement with FMS which is subject to the successful

raising of capital and listing. FEX can acquire a 51% interest by spending $3.5 million in

two years and a total 75% interest by spending a total $6.0 million on exploration within a

total three years. The JV contains a substantial tenement package which is prospective for

phosphate, diamonds, copper and gold.

• Further Details: FEX is seeking to raise $5,000,000 by the offer of 25,000,000 shares at a

price of 20 cents per share and will accept oversubscriptions of a further $2,000,000.

Key Investment Highlights• Objective: to achieve sustainable production ASAP

• Copper Claim: Prefeasibility study, including drilling and column leach tests, mining lease

application.

• Black Cat: Prefeasibility study, pit optimisations, extension drilling, mine design – followed by

contract mining, ore haulage and toll treatment and production

• Porters Mount: Deep drilling at 200-500 metres depth searching for a world class target

• Diamonds and Phosphate: Bulk sampling and drilling leading to follow up work.

MINING

Board & Management:

Andrew Andrejewskis – ChairmanAndrew brings 43 years of experience in senior roles in the resources industry and government.

David Tucker - Managing DirectorDavid is a minerals geophysicist and has more than 37 years experience in the minerals exploration industry.

Kevin Wills - Executive DirectorKevin has 36 years experience and was the former Managing Director of Flinders Mines.

Further InformationTo learn more about this opportunity go towww.wholesaleinvestor.com.au and search for Flinders Exploration.

Flinders Exploration

Mining

2009

IPO

Adelaide, SA

IPO Capital

Company Name

Sector

Year Established

Business Stage

Location

Seeking

EARLY BOOKING RATE: $295*AVAILABLE UNTIL 31 AUGUST 2011

Register immediately as places are limited.

* GST inclusive. Conference fee includes attendance at the two

day conference, meals, networking function, conference program

and research notes.

For further information and to register visit www.microcapconferences.com or call 03 8352 7140

Event Partners

Media Partner

Professional investors are invited to attend the

2nd Annual Australian Microcap Investment Conference

OVER 2 DAYS:

Tuesday, 18 October 2011 andWednesday, 19 October 2011 Sofi tel Melbourne On Collins, Melbourne

• Adelaide Energy Limited (ADE); an oil and gas exploration and production company focused on the Otway and Cooper Basins in South Australia.

• Advanced Braking Technology Limited (ABV); is dedicated to the development of innovative braking systems including the Sealed Integrated Braking System (SIBS®).

• Australian Power & Gas Company Limited (APK); Australia’s leading electricity and gas provider. Ranked number one on BRW’s 2010 Fast 100 List.

• Central Petroleum Limited (CTP); a junior exploration and production company operating the largest holding of prospective onshore acreage in Australia totalling over 70 million acres.

• Circadian Technologies Limited (CIR); is a biotechnologies company focused on the treatment of cancer and other serious human illnesses.

• Diploma Group Limited (DGX); a leading property development, construction and realty company with a diverse commercial, retail and residential portfolio.

• Gold Road Resources Limited (GOR); a gold exploration company focused on the Yamarna Belt in WA.

• Healthzone Limited (HZL); Australia’s leading natural products distributor, franchise retailer and producer of health, beauty and natural products.

• Integrated Legal Holdings Limited (IAW); is focused on the steady and selective acquisition of legal fi rms to develop a national network of law fi rms.

• Ipernica Limited (IPR); extensive global activities focused on generating revenue from intellectual property (IP) rights.

• Jumbo Interactive Limited (JIN); a successful online lottery business that has created the hugely popular Oz Lotteries website.

• MNET Group Limited (MNZ); Australia’s leading full service mobile solutions company and partner for many of the world’s leading telecommunication carriers and media companies.

• NewSat Limited (NWT); Australia’s largest independently operated satellite communications company.

• Neon Energy Limited (NEN); a petroleum exploration and production company with oil and gas interests in Vietnam and California.

• Patrys Limited (PAB); a biotechnology company with its core technology to identify and harvest antibodies produced by the human body in response to tumours.

• Praemium Limited (PPS); a specialist in the provision of investment administration and portfolio management services to Australia’s leading fi nancial institutions.

Companies presenting include:

The smart money knows that some things are best kept to oneself. Perhaps that’s why you might not know about the broker that’s quietly become one of Australia’s leading financial services firms.

Patersons Securities has been Australia’s most active in new capital raisings since 2007 and raised in excess of $6.6 billion in over 760 new issues over the past decade. Patersons has frequently been ranked first by number of new equity issues in Australia and continues to be so in 2010 with 16.4% of the market.

Our Research team was recently awarded #1 stock picker in the Real Estate sector, #1 stock picker in the Metals and Mining sector and #2 stock picker in the Energy sector at the 2010 Thomson Reuters StarMine Analyst Awards.

To be eligible to participate in Patersons new deal flow you must have net assets of at least $2.5 million or gross income of $250,000 or more for each of the last two years.

This is intended to provide general advice only, and has been prepared without taking account of your objectives, financial situation or needs and therefore before acting on advice contained in this advertisement you should consider its appropriateness having regard to your objectives, financial situation and needs. You should only seek to participate in offers as a sophisticated investor if you have previous experience in investing in securities, so you can assess the merits of an offer, the value of securities, the risks involved in accepting the offer, the adequacy of the information in respect of the offer and whether it is suitable to your circumstances.

Patersons Securities Limited ABN 69 008 896 311 AFSL No. 239 052 Participant of ASX Group; Participant of NSX Group; Stockbrokers Association of Australia Principal Member; Financial Planning Association Principal Member

www.psl.com.au T H E AU ST R AL I A N STO C KB RO KE R

Never heard of the most active broker in new capital raisings?

To receive a complimentary sample of our research or to talk about Patersons new deal flow, please contact Marco Longo or Michael Brindal on 03 8803 0167 or email corporatedeals@psl.com.au.

The smart money likes it that way.

43

Company Name Code Business Stage Sector

Listing Index

Mining

Global Media Distribution

Biotech

Biotech

Healthcare/Biotech

Financial Services

Property

Technology

Funds Management

Clean Technology

Technology

Biotech

Cleantech

Cleantech

Clean Tech

Food / Diet Programs

Cleantech

Technology

Cleantech

Professional Services

Resources

Biotech

Property / Development

Biotech

Gaming

Biotech/Healthcare

IT

Biotech

Biotechnology

Technology

Mining

Financial Services

Agribusiness

Healthcare

Healthcare/Biotech

Baraka Energy & Resources Ltd (ASX: BKP)

Because Group International

Benitec Bipharma

BioDiem Ltd

Bionomics Limited (ASX:BNO)

Bizpanel Limited

BlackWall SPORTSMED Property Trust

Bluechiip Ltd

Bullion Capital

Carbon Conscious Ltd (ASX:CCF)

Collective Intelligence Group

Cynergy Health

Diamond Energy

Eastern Harmony NZ Ltd

Eastland Medical Systems Limited (ASX:EMS)

EcoQuest Limited (ASX:ECQ)

Equiome

Exa Web Solutions

Flinders Resources (ASX: FEX)

Folkestone (ASX: FLK)

Forza Capital Pty Ltd

Global Kinetics Corporation

Intellect Projects Pty Ltd

Jubilent Health Australia Ltd

KFSU Pty Ltd

Mesthynes Ltd

Mint Wireless Limited

Photonz Corporation Ltd

Phylogica Limited (ASX:PYC)

Qanda Technology Ltd

Sun Connect

Third Link Growth Fund

TRAC Financial

WH Medical Pty Ltd

Xenexus Pharmaceuticals Ltd

BKP

BCI

BLT

BDL

BNO

BZP

BWS

BCT

BUL

CCF

CLG

CYN

DIA

EHNZ

DIA

ASY

ECQ

EWS

ERJ

EQU

FEX

GKC

INP

JHA

JIN

MSY

MNW

PTZ

PAB

QNA

RXL

TLG

TFF

WHM

XNP

BKP

BCI

BLT

BDL

BNO

BZP

BWS

BCT

BUL

CCF

CLG

CYN

DIA

EHNZ

DIA

ASY

ECQ

EWS

ERJ

EQU

FEX

GKC

INP

JHA

JIN

MSY

MNW

PTZ

PAB

QNA

RXL

TLG

TFF

WHM

XNP

Further InformationFor information on these and other opportunities, go to www.wholesaleinvestor.com.au

How cangrowing abusiness make you feel like an emperor?

When our Private Clients teamspoke with brothers Emanuel andNapoleon Perdis, of Napoleon PerdisCosmetics, they had outgrown theirlocal advisor and were looking toexpand. Emanuel wanted someonewho could work with them onexpansion plans and refinancing,but more importantly, he neededa trusted business advisor hecould come to for future decision-making. Their unique take on thecosmetics industry – that they’renot in the fashion business, but theconfidence boosting business – hasseen them grow and grow. With thecontinued advice of their PrivateClients team, they are now on theirway to becoming one of the mostrecognised cosmetics brandsfrom Australia to Hollywood.And Emanuel, he loves the fact thatalthough he’s not our only client,he certainly feels like he is.

What would you like to grow?Share your story at whatwouldyouliketogrow.com.au